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ABSTRACT 
Levels of Insulin-like growth factor I (IGF-1) are reduced in several neurological 
disorders, including aging and neurodegeneration. Aged animals have reduced IGF1 signaling 
and exhibit impairment in cognition. Supplementing rodents with IGF-1 reverses some of the 
cognitive deficit, suggesting that IGF-1 signaling could potentially be targeted to ameliorate 
cognitive decline in older adults. For this, a thorough understanding of the mechanisms by which 
IGF-1 regulates the function of various cell types in the brain is needed. A majority of studies 
have focused on the effects of IGF-1 regulating neurons. However, astrocytes that form roughly 
about 40% of brain mass also produce IGF-1 and express IGFR. Studies have shown that IGF-1 
regulates some of the astrocytic functions like glucose uptake. Based on these observations, we 
hypothesized that loss of IGF-1 signaling disrupts astrocyte structure, and its critical function of 
glutamate-glutamine cycling, ultimately affecting cognition.  
To test this, we used a combination of pharmacological and genetic manipulations to 
reduce IGFR in cultured astrocytes and mice. We observed that loss of IGF1 signaling in 
astrocytes decreases uptake of glutamate by decreased trafficking or expression of glutamate 
uptake transporter machinery. To test the effect of loss of astrocytic IGF-1 signaling on 
cognition, we generated a mouse model of inducible astrocytic IGFR deficiency by crossing 
homozygous igfrf/f mice with iGFAP-Cre mice using tamoxifen. We then assessed the role of 
astrocytic IGFR in regulating behavior using a battery of behavioral assays. Consistent with the 
in vitro results, we observe disrupted glutamate handling and neurotransmitter cycling in the 
brains of astrocyte-specific IGFR (aIGFR) KO animals. Additionally, we also observe increase 
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in the levels of urea in the brain, which is indicative of neuronal stress. aIGFR knockout animals 
do not show any impairment in cognition, suggesting astrocytic IGFR does not contribute to 
cognitive decline due to loss of IGF-1 Thus, loss of IGF-1 signaling in astrocytes affects 
glutamate homeostasis which may contribute to the development of an excitotoxic phenotype 
observed in aging and neurodegeneration. Overall, this project helped uncover critical aspects of 
IGF1 regulation of astrocyte structure, function and cognition. 
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CHAPTER 1 INTRODUCTION 
1.1 Overview of Insulin-like growth factor 1 (IGF-1) 
1.1.1 Growth-factors and their actions in the body 
Growth factors are substances that promote growth, cell proliferation, differentiation 
and longevity throughout the body. Some examples include the Epidermal growth factor 
(EGF), Insulin-like growth factor (IGF), Brain-derived Neurotrophic factor (BDNF), Glial-cell 
line derived neurotrophic factor (GDNF), Vascular Endothelial Growth Factor (VEGF), 
Fibroblast growth factor (FGF), and nerve growth factor (NGF). In the brain, all major cell 
types are influenced by growth factors. IGF-1, BDNF, and GDNF promote neurogenesis in the 
hippocampus and neuroplasticity (Cameron et al., 1998; Fuchs & Flügge, 2014; Lee & Son, 
2009; Oliveira et al., 2013). Additionally, FGF is known to increase the number of newborn 
glia (Kuhn et al., 1997). Some of these growth factors or their decline are implicated in several 
neurological disorders (Connor & Dragunow, 1998). Importantly, supplementation or 
overexpression of growth factors have been found to be neuroprotective in neurodegenerative 
diseases (Hanson & Frey, 2008; Schindowski et al., 2008) and ischemia in rodents (Duarte et 
al., 2012). Therefore, growth factor signaling has been considered a potential target for 
slowing or reversing aging, neurodegeneration, brain injury, repair and regeneration. 
Many growth factors are expressed in the brain or are readily transported to it through 
the blood-brain-barrier (BBB). One such growth factor is Insulin-like growth factor (IGF-1), 
also called Somatomedin C in the older nomenclature (Reinhardt & Bondy, 1994). IGF-1 is 
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critical for normal growth and development, and starts declining with age after puberty (Deak 
& Sonntag, 2012; Sonntag et al., 2001). Since IGF-1 is an anabolic hormone, it cannot be 
administered systemically to patients because it is implicated in several cancers (Baserga et al., 
2003). Unfortunately, delivery of IGF-1 to the brain is challenging as this peptide is not orally 
bioavailable. As a result, it becomes crucial to study the downstream signaling pathway of 
IGF-1 for developing a potential therapy against neurological disorders. 
1.1.2 Structure of IGF-1 
The IGF-1 protein is encoded by a single gene that has six exons. This gene undergoes 
alternate splicing to produce different mRNA transcripts that in turn produce different pre-pro- 
IGF-1 proteins. Interestingly, despite the existence of multiple isoforms, their cleavage always 
yields the same final IGF-1 single chain polypeptide made up of 70 amino acids with a 
molecular weight of 7649 Da (van Dijk et al., 1991). As the name suggests, the structure of 
IGF-I is homologous to proinsulin. Specifically, amino acids from one to twenty-nine exhibit 
homology to Insulin B chain, while forty-two to sixty-two are homologous to Insulin A chain. 
Positions 30 to 41 constitute the connecting peptide in the case of IGF-1, which does not show 
any homology to proinsulin C peptide’s connecting sequence. Another feature of the IGF-1 
protein that is different from the insulin protein is an octapeptide sequence at the COOH-
terminal end, not found in proinsulins. Across species, IGF-1 is a relatively conserved protein. 
Owing to its homology with insulin, IGF-1 and insulin signaling pathways are known to 
exhibit cross-reactivity (Oberbauer, 2013; Rinderknecht & Humbel, 1978).  
1.1.3. Expression and Regulation of IGF-1 
Nearly 70-75% of the total IGF-1 in the human body is secreted by the liver and 
circulates in the blood to be transported to its site of action (Ohlsson et al., 2009). In the liver, 
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expression of the igf1 gene is regulated primarily by growth hormone (GH). The hypothalamus 
produces growth hormone releasing hormone (GHRH), which in turn controls the pulsatile 
release of growth hormone from the pituitary gland. When growth hormone acts on growth 
hormone receptor (GHR) in hepatocytes of the liver, IGF-1 is produced. The stepwise secretion 
of these hormones is regulated via a negative feedback loop facilitated by the presence of 
IGFRs in the pituitary and hypothalamus which sense the excess levels of IGF-1 (Berelowitz et 
al., 1981; Wood et al., 1989). Circulating IGF-1 is capable of passing through the BBB into the 
CSF with the help of the low-density lipoprotein receptor- related transport protein (LRP) 
(Carro et al., 2005). Thus, hepatic-derived IGF-1 can enter the brain and influence the brain 
microenvironment. 
In addition to the liver, it is also produced and secreted locally in a number of tissues. 
This local expression is also controlled by GH as well as tissue specific factors that tightly 
regulate transcription and post-transcriptional levels (Frystyk, 2004). In the brain, IGF-1 is 
released by a number of cells including microglia, neurons, astrocytes, oligodendrocytes and 
brain microvascular endothelial cells. IGF-1 released from these cells may act in a paracrine 
and autocrine manner as these cells also express IGFR. Expression of IGF-1 is variable and 
depends on several conditions like the stage of development, type of cell or tissue, and the 
presence of a pathology (Shiratsuchi et al. 2011). 
1.1.4. IGF-1, IGF-BPs and the BBB 
Once released by the liver, the IGF peptide is susceptible to degradation in the 
bloodstream (Bach, Headey, & Norton, 2005). Protection from degradation and transportation 
to the target tissues are facilitated by IGF-binding proteins (IGFBPs), which stabilizes IGF-1 
and modulates its availability and half-life. There are ten IGFBPs in total, out of which 
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IGFBPs 1-6 have a very high affinity for IGF-1 due to their highly conserved C-Terminal and 
N-terminal domains that bind to IGF-1 (Bach et al., 2005; Jones & Clemmons, 1995). Studies
have shown that the expression of IGFBPs depends on a number of factors like exercise, 
nutrition, age, and diseased conditions. There have been attempts to inhibit IGFBPs for 
treatment of cancers (Jones & Clemmons, 1995); however, this would reduce the availability 
of IGF1 throughout all the tissues. Although IGFBP3 is implicated to be upregulated in 
Alzheimer’s disease, little is known about targeting IGFBPs in the brain (Watanabe et al., 
2015). 
1.1.5. IGF-1 versus IGF-2 
In addition to IGF-1, the IGF family also includes IGF-2. These proteins are highly 
homologous to each other and exhibit a 62 % similarity in their amino acid sequences 
(Marshman & Streuli, 2002; Pacher et al., 2007). Both of IGF-1 and IGF-2 are circulating 
polypeptides and bind to the IGF-1R for exerting their biological activities (Jones & 
Clemmons, 1995; Winston et al., 2006). Just like IGF-1, IGF-2 is also transcribed by almost 
all cells and is tightly regulated at the transcriptional and post-translation levels. Unlike IGF-1, 
serum levels of IGF-2 remain high throughout adulthood in humans. In fact, they are 3.5 times 
higher than serum IGF-1 levels in adulthood or old-age (Frystyk, 2004; Yakar & Adamo, 
2012). While IGF- 2 is capable of binding to and activating IGF1R, it has a low affinity 
towards this receptor and a much higher affinity towards non-signaling IGF2R (Bergman et 
al., 2013). Thus, IGF-1 is more likely to exert IGF1R dependent effects throughout the body, 
than IGF2. 
1.1.6. IGF-1 signaling pathways 
Activation of IGF1R initiates signal transduction cascades associated with cell growth, 
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proliferation and longevity. On binding to IGF1, IGF1R initiates autophosphorylation of 
tyrosine residues on the β-subunit intracellular component of these receptors. This in turn 
causes a phosphorylation of various substrates including IRS1, 2 and Shc. Proteins containing 
the SH2 domain then recognize these phosphorylated substrates and bind to them. This allows 
for various effector proteins to bind to the autophosphorylated docking sites and, depending on 
which effector protein is bound, distinct downstream cascades can be initiated. 
The signaling cascades that regulate the downstream effects of IGF-1 can be classified 
into two important pathways: The Ras/mitogen-activated protein kinases (MAPK) pathway 
(Ras/ MAPK) and the phosphatidylinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway 
(PI3K/Akt). In the Ras/MAPK pathway, following autophosphorylation, a docking protein 
containing SH2 domain like growth factor receptor-bound protein 2 (GRB2) binds to it. 
Another molecule called SOS then binds to the GRB2 as well as Ras. On activation, it initiates 
the cascade causing phosphorylation of ERK by MEK, ultimately activating the transcription 
factors Jun and fos allowing for cell proliferation. A second pathway called PI3K/Akt is also 
initiated in a similar manner depending on which tyrosine residues are activated on the IRSs. 
Binding of PI3K to the IRSs phosphorylates it, after which it binds to phosphatidylinositol 
4,5-biphosphate (PIP2) to become phosphatidylinositol 3,4,5-triphosphate (PIP3). This in turn 
activates Akt. Akt can inhibit apoptosis, or programed cell death, by binding to B-cell 
lymphoma 2 (BCL2)- associate X protein (BAX). Activation of Akt can phosphorylate Ras 
homolog enriched in brain (RHEB), which activates mammalian target of rapamycin (mTOR), 
which in turn activates the translation factor S6 kinase (S6K). S6K then binds to ribosomes 
promoting protein synthesis. Additionally, Akt promotes proliferation by decreasing the 
concentration of forkhead box O (FOXO), inhibiting proliferation. 
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Figure 1.1. Summary of IGF-1 signaling pathway 
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1.1.7. IGF-1 and development 
IGF-1 plays an extremely crucial role in development as demonstrated by several 
studies in humans and animal models. One study examining IGF-1 deficiency in both humans 
and animals, showed that newborns with Laron syndrome-a condition of IGF1 deficiency, are 
shorter than normal babies (42-45 vs 49-52). Additionally, these patients exhibit a slower 
growth rate after birth, also exhibiting a suboptimal organ development (including the brain, 
heart, genitalia and skeletal muscles). Additionally, deficiency of IGF-1 in humans leads to 
dwarfism (Laron, 2001). IGF-1 null mice exhibit a number of developmental defects in utero 
and most offspring do not survive. Of the mice that do survive, they are reported to be at about 
65% of their normal weight at birth. Similarly, IGF-1 receptor null mice weigh 55% of normal 
weight; however, many die within a few hours due to respiratory failure. The ones that do 
survive show underdeveloped lung, skin, bone, and cognitive impairments (Zhou et al., 1997). 
IGF-1 has also been shown to be crucial for normal development of skeletal muscles (Yakar & 
Adamo, 2012). Overall, studies conducted using various transgenic mouse models point 
towards the fact that IGF-1 is critically important for normal growth and development of 
various organs. 
Paracrine and Autocrine signaling of IGF-1 in the brain 
As mentioned, neurons as well as most of the glial cell types secrete IGF-1. After 
puberty the levels of circulating IGF-1 drop, yet autocrine and paracrine IGF-1 continues to be 
produced locally in the brain. Levels of IGF-1 in the brain tissues drop with advanced age 
(Sonntag et al., 2001). This is further supported by the fact that global loss of IGF-1 can cause 
cognitive deficit in children, and can also cause microcephaly (Netchine et al., 2011). 
Additionally, impaired GH signaling still allows for normal cognitive functions (D’Ercole & 
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Ye, 2008). Thus, for development of therapies that reverse or slow down cognitive decline, 
disrupted paracrine/autocrine IGF-1 signaling which is associated with it, needs to be explored. 
1.2. IGF-1’s correlation with neurological disorders 
1.2.1. IGF-1 and the age-associated cognitive decline 
For targeting the autocrine/paracrine signaling of IGFR, it is first imperative to 
understand the relationship between IGF-1 and cognition from a clinical standpoint as well as 
on a molecular level. 
Aging is almost always accompanied by cognitive decline. While some aged 
individuals do not exhibit dementia, most individuals show a decreased processing speed and a 
decreased ability to learn. A stage between aging-associated cognitive decline and dementia is 
showing Mild Cognitive Impairment (MCI), which makes one more susceptible to 
neurodegenerative diseases like Alzheimer’s disease (AD). Data from animal models indicate 
that age-associated cognitive decline may be reversible. Therefore, therapies that could allow 
for a possible reversal, delay or arrest of cognitive decline need to be developed. 
With respect to the aging brain, the field has contradictory opinions regarding the 
relationship of cognitive decline with IGF-1 levels (Frater et al., 2018; Sonntag et al., 
2005). Circulating IGF-1 levels start declining after puberty. However, cognitive 
impairment is not observed until many years later (Yamamoto et al., 1991). Interestingly, in 
addition to circulating IGF-1, we also observe a decline in IGF-1 levels in the CSF and 
brain tissues. Although a compensatory effect to restore IGF1 signaling is seen in response 
to the declining levels of IGF-1, it is still not sufficient to ameliorate the cognitive decline 
(Ashpole et al., 2015). 
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Studies in humans 
In humans, the decline of IGF-1 in middle-aged and older is associated with cognitive 
deficits (Doi et al., 2015; Wennberg et al., 2018). Studies have explored sex-specific 
differences in IGF-1 levels and cognition in older adults. In women, IGF-1 levels are 
positively correlated with cognition (Wennberg et al., 2018), while in middle-aged and older 
males, an inverse relationship is observed (Tumati et al., 2016). Baseline levels of serum IGF-
1 measured in older men and women, can be positively correlated with cognition in women 
(Okereke et al., 2006; Okereke et al., 2007) but not men (Green et al., 2014). As per another 
study on longevity, women with lower IGF-1 levels have better cognition (Perice et al., 2016). 
Hormone replacement therapy in older adults reverses some of the cognitive decline 
associated with loss of IGF1 in age (Deijen et al., 1998). Thus, the studies performed in 
humans has led to data that is mixed and do not offer a concrete conclusion about IGF-1 levels 
and cognition, partly due to multiple tools, designs and criteria for assessing the same. 
Animal and molecular studies 
The liver-specific knockout mice (LID), which exhibit a 70% reduction in global 
IGF-1 levels, show deficits in hippocampal-dependent spatial learning and memory (Trejo, 
LLorens- Martín, & Torres-Alemán, 2008). Additionally, loss of liver-derived IGF-1 alters 
neurovascular coupling in mice (Toth et al., 2015). Intraverebroventricular (ICV) infusion of 
IGF-1 to old-male rats reverses the cognitive decline associated age. Additionally, it also 
increases neurogenesis in hippocampus (Anderson et al., 2002; Casadesus et al., 2004; 
Lichtenwalner et al., 2001; Markowska, et al., 1998; Yuan et al., 2015). In female old rats, 
ICV administration not only improves spatial learning and memory, and neurogenesis, but 
also transcription of genes related to synaptic plasticity (Pardo et al., 2016). Molecular 
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studies indicate that IGF-1 promotes neuronal growth, proliferation and excitability, and 
increased synaptogenesis (Torres-Aleman, 2010; Xing et al., 2007) thereby regulating 
pathways associated with cognition. 
1.2.2. IGF-1 and Alzheimer’s disease 
IGF-1 signaling dysregulation has been implicated in neurodegenerative disorders, 
like Alzheimer’s disease (AD), which is characterized by the deposition amyloid beta protein 
deposits extracellularly, and intracellular neurofibrillary tangles made up of tau protein. 
Additionally, AD is accompanied by dementia and a progressive decline in all cognitive 
functions. 
Studies in humans 
AD patients with lower serum IGF-1 levels exhibit faster cognitive decline, implying 
that IGF-1 plays a protective role (Vidal et al., 2016). On the contrary, another prospective 
study shows a negative correlation between AD and serum IGF-1 levels (Westwoo et al., 
2014). Additionally, a clinical study evaluating the use of a Growth Hormone secretagogue 
MK-677 in AD patients, has showed that serum IGF-1 levels increase by 60%. However, no 
improvement with AD-associated cognitive decline is observed, indicating a more complex 
relationship of IGF-1 levels and cognition in AD (Sevigny et al., 2008). 
Animal and molecular studies 
When IGF1R is knocked out in neurons, an increased clearance of amyloid plaques is 
observed (Bitto et al., 2010). Also, treatment with exogenous IGF-1 has shown amelioration of 
the neurotoxic effects caused by amyloid beta peptides in cultured cells as well as animal 
models (E. Carro et al., 2002; Niikura et al., 2001). Furthermore, IGF-1R antagonism in the 
choroid plexus causes deposition of beta amyloid in the brain. One study has shown 
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contradictory data indicating that decreasing IGF-1R activity in the brain ameliorated AD 
associated impairment (Cohen et al., 2009). Another rigorous study showed that the 
supplementing IGF-1 failed to alter beta amyloid levels in transgenic mice, rats, and dogs 
(Lanz et al., 2008). Thus, targeting IGF-1 as a therapy for treatment of AD would be extremely 
challenging owing to these contradictory results and mixed observations. Indeed, a meta-
analysis of all the studies in humans and mice with targeting IGF-1 signaling shows that there 
is no association between AD and IGF-1 levels (Ostrowski, et al., 2016). 
1.2.3. IGF-1 and Parkinson’s disease 
The second most common neurodegenerative disorder after AD is Parkinson’s disease 
(OD), characterized by the deposits of alpha-synuclein in dopaminergic neurons in the 
substantia nigra region. It is clinically characterized by the presence of tremor, bradykinesia and 
rigidity. 
Studies in humans 
An increase in the duration/progression of PD has been negatively correlated with IGF-
1, GH and IGFBP-3 levels (Godau et al., 2010; Godau et al., 2011; Tuncel et al., 2009). This 
indicates an initial protective role for IGF-1 in combating the PD-associated abnormalities in 
function. Some studies also suggest that the initial higher level of IGF-1 maybe an indication for 
risk of worsening of PD. A prospective study in PD patients confirmed the latter notion and 
reported that initial higher serum IGF-1 levels can be correlated to worsened PD pathology 
(Picillo et al., 2013). 
Contrasting with the findings described above, an improvement in PD symptoms after 
the exact same duration of the study in patients who had higher basal serum IGF-1. This backs 
up the notion that basal serum IGF-1 does play a protective role initially. Taken together, these 
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studies indicate that more controlled studies are needed in order to infer a correlation between 
serum IGF-1 levels and PD progression. 
Animal and molecular studies 
In animal models of PD, IGF-1 signaling has an anti-oxidative and anti-inflammatory 
effect (Nadjar et al., 2009; Quesada & Micevych, 2004). In DA neurons and rat PC12 cultures 
too, IGF-1 has been shown to have neuroprotective effects (Offen et al., 2001; Sun et al., 
2010) by an increase in the number of DA neurons and expression of anti-apoptotic proteins. 
However, in Drosophila and C. elegans reduced IGFR signaling is neuroprotective (Knight et 
al., 2014). This highlights a complex relationship between IGF-1 and PD. 
1.2.4. IGF-1 and Stroke 
Studies in humans 
Inconsistencies between the relationship of IGF-1 levels and neurological effects have 
been reported before, during, and after an ischemic stroke. The levels of IGF1 were lower in 
patients with an ischemic stroke as compared to healthy controls, highlighting increased risk 
with reduced IGF-1. This difference in IGF-1 levels was observed for at least 10 days, 
following the insult. Also, the decline in the levels correlated with the severity of stroke-
induced damage. Other studies also report that IGFBP3 levels were reduced along with IGF-1 
levels in the serum for some days after the stroke (Denti et al., 2002; Denti et al., 2004; 
Schwab et al., 1997; Tang et al., 2014). 
Some studies report contrasting results to the ones described above. One study did not 
find any correlation between IGF-1 levels and stroke, while another one reported elevated 
serum IGF-1 levels within the first ten days after a stroke (Åberg et al., 2011; De Smedt et al., 
2011). The notion that this temporary elevation in IGF-1 levels is protective is supported by 
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studies that observe improved cognitive outcomes in these patients (Bondanelli et al., 2006). 
Animal and molecular studies 
After a stroke, both locally-derived and liver-derived IGF-1 are shown to have a 
neuroprotective effect in animal models. Consistent with the studies in humans, the levels of 
IGF-1 are elevated in the region surrounding the infarct. Interestingly, this elevation is 
observed in astrocytes present around the damaged area (Yan et al., 2006). A study showed 
that if serum IGF-1 levels are higher before performing Middle Cerebral Artery Occlusion 
(MCAO) to induce stroke, the degree of damage is higher (Endres et al., 2007). In rodent 
models of injury, supplementing with IGF-1 administered ICV improves outcomes and is 
neuroprotective (Mackay et al., 2003; Schäbitz et al., 2001). Other routes of administration of 
IGF1 can prove to be just as effective. Neuroprotective effects of IGF1 are also observed in 
hippocampal cell cultures subjected to hypoxia (Mackay et al., 2003). Therefore, taken 
together, these data suggest that IGF-1 levels may rise for a short while after an ischemic event 
or injury to likely reduce or reverse the damage caused by the event.  
1.3. Duality of IGF-1 activity in the brain: need for examining the effects of IGF-1 on other 
brain cell types 
IGF-1 has both positive and negative effects as described above, that may be 
influenced by the diseased state, age, nutrition, environmental condition and so on. A 
physiologically beneficial effect may turn out to be harmful under certain conditions of the 
brain microenvironment, thus leading to contradictory findings. Therefore, it becomes crucial 
to understand the cell-specific effects of autocrine/paracrine IGF1 signaling. 
1.4. Astrocytic physiology and pathophysiology in the brain 
Astrocytes are the predominant cell type in the brain. They are not just support cells that 
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glue together the brain mass, but also actively take part in regulating the microenvironment. 
Astrocytes are involved in the uptake of glutamate from the synapse after the completion of 
neurotransmission, and regulate the glutamate-glutamine cycle in the brain. By doing so, they 
provide neurons with glutamine, and also regulate the metabolic cascades to main the 
bioenergetics in the brain. They release trophic factors including IGF-1 and BDNF that promote 
cell survival and longevity in neurons, and promote synaptogenesis. Together with the 
microglia, astrocytes regulate immune response in the brain. They also help maintain the 
integrity of the BBB, and form a part of the glymphatic system that gets rid of toxic substances, 
collectively protecting the brain. Astrocyte dysfunction has been the focus of studies examining 
neurodegeneration and impaired metabolism. The rationale of studies that focus on astrocyte 
dysfunction to develop potential therapies is that, preventing or reversing astrocyte dysfunction 
could contribute to slowing down the onset cognitive decline (if astrocyte dysfunction starts to 
occur before cognitive decline) or reverse/arrest/slow down cognitive decline (if it happening 
before astrocyte dysfunction). 
Literature studies: Influence of IGF1 on astrocyte function 
Interestingly, astrocytes express both IGF-1 and IGF1R. Studies suggesting 
overexpression of IGF-1 in astrocytes proves to be neuroprotective against injury both in 
rodent models and culture (Madathil and Saatman, 2015). Additionally, astrocytes produced by 
IGF-1 can act in a paracrine manner on neurons, microglia and other cells in the brain. 
Astrocyte-derived IGF-1 protects neurons from oxidative stress in culture as described above. 
Additionally, IGF-1 also upregulates the expression of glutamate transporter EAAT1 (Suzuki 
et al., 2001), thereby suggesting a role in regulation of the glutamate-glutamine cycle 
regulation. Thus, a thorough examination of astrocytic IGFR signaling and the role it plays in 
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influencing astrocyte function is needed. 
1.5. Value-addition to existing literature: Significance of the project 
A tremendous advancement in medicine and healthcare has led to an increase in the 
average life span of people all around the world. However, this also means that a growing 
population will be susceptible to diseases of aging and neurodegeneration. In the year 2050, 
the US population above the age of 65 is predicted to be around 83.7 million. This is almost 
double the estimated population of 43.1 million in 2012 (Ortman et al., 2014). As discussed, 
aging of the brain is associated with a reduction in cognition, significantly affecting the 
patient’s ability to lead a normal independent life. It also poses an enormous economic burden 
on them and their families. Though aging is a natural process and is inevitable, the cognitive 
impairment associated with it, is a matter of growing concern because of its morbidity. 
According to CDC, about 5.1 million Americans aged 65 years or higher may have 
Alzheimer’s disease. This figure is predicted to increase to 13.2 million by 2050 (CDC, 2011). 
Therefore, it is imperative to find an effective therapy for aging associated cognitive 
impairment. 
To recap, growth factors in our body control anabolic and cell proliferative activities, 
and thereby regulate overall growth. IGF-1 exerts neuroprotective effects and regulates 
learning and memory (Aleman et al., 2009; Torres-Aleman, 2010; Trejo et al., 2008). The 
levels of circulating IGF-1 slowly decline with age, and are associated with cognitive 
impairment in humans as well as rodents (Ashpole et al., 2015). Importantly, supplementation 
of IGF-1 in aged animals reverses cognitive deficits (Markowska et al., 1998). Most of the 
IGF-1 research has focused on the regulation of learning and memory by regulating the 
neuronal structure and increasing the excitability of the neurons themselves (Xing et al., 
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2007). However, the contributions of support cells like astrocytes has been largely ignored. It 
is possible that IGF- 1 may promote learning and memory by also regulating the function of 
astrocytes. This project aimed to bridge the gap in knowledge regarding the role of IGF-1 in 
regulating astrocytes. 
1.5.1. Overview of the Lox-Cre system 
Gene editing has proven to be one of the most crucial tools one can utlize to study the 
function of a gene/protein by allowing for knock-out and knock-in models. Here, we utilized 
the Cre-LoxP system to knock out IGFR in astrocytes. The Cre-LoxP system has been in 
extensive use owing to the simplicity of gene editing. The system was discovered in 
Bacteriophage P1 (Sauer, 1998) and consists of two components: an enzyme called Cre 
recombinase or Cre and specific DNA sequences called loxP (locus of x-over, P1) sites. Cre is 
a tyrosine site-specific recombinase (T-SSR) and recognizes two repeated loxP sites, which is 
a sequence made up of 34 bp. After recognizing the site, Cre mediates site-specific removal of 
DNA between two loxP sequences. 
What is most appealing about the application of this technique is the creation of 
conditional knockout models which allow for a spatial and temporal control. This is 
particularly important when it comes to studying proteins that are dysregulated sporadically, or 
until later in life, or those that are essential for early development. It helps us create functional 
knockout animals that are exhibit the phenotype similar to the disease being studied, while not 
introducing the confounding developmental defects that are seen with traditional knockouts. To 
generate inducible knockout mice models using the Cre-Lox P system, the expression of Cre-
recombinase needs to be driven under a promoter gene specifically targeting in the cell or 
tissue of interest. Additionally, temporal control over the expression of Cre can be achieved by 
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administering molecules that stimulates the fused promotor to express Cre in the specific cell 
type (Feil et al., 2009; Hayashi & Hayashi, 2007; Sauer & Henderson, 1988). 
1.5.2. Astro-specific IGFR deficient (AID) animals’ generation 
As IGF-1 is so crucial for the normal development of the brain and other organs, we 
wanted to knock down IGFR in mice after puberty. Since the aim of this project was to 
specifically examine the effect of astrocytic IGFR deficiency, we made use of the Cre-LoxP 
system which allowed us to have a spatial and temporal control over knock down of IGFR 
gene in mouse astrocytes. To do this, we require a Cre-driver strain where Cre recombinase is 
expressed by a promoter that specifically targets the astrocytes, i.e. GFAP. This mouse strain 
is readily available at the repository of the Jackson laboratories. Second, loxP flanked (floxed) 
IGFR DNA containing mouse strain would need to be established. Fortunately, this strain is 
also available through the repository of Jackson laboratories. By breeding the iGFAP-Cre 
strain with a floxed mouse strain (Exon 3 of IGFR) several times, a mouse line expressing 
both the iGFAP- Cre and floxed IGFR gene would be generated. The specificity and timing of 
recombination could then be controlled by using a substance like Tamoxifen, which would 
bind to the ER receptor fused to the GFAP promoter and drive the expression of Cre 
recombinase. Cre would then recognize the loxP sites flanking IGFR exon 3 and excise it. 
1.6. Research Goals: 
Astrocytes do more than just exist as supportive cells in the brain. They are major 
regulators of buffering of toxic signals and release a variety of neuroprotective and neurotrophic 
factors. Additionally, they also cycle gliotransmitters/ neurotransmitters, take part in 
metabolism, and couple the neurovascular response. Thus, under normal physiological 
conditions, they play a crucial role in the regulation of microenvironment in the brain, thereby 
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making it conducive for neurons as well as other brain cells (Eroglu & Barres, 2010; Parpura & 
Haydon, 2009). Considering all these factors, dysregulation of astrocytes could contribute to a 
disruption of this microenvironment, ultimately affecting cognition. Aging and age-related 
neurodegenerative diseases are associated with increased levels of astrogliosis (or “activated 
astrocytes”) and impaired astrocyte function. 
Overall hypothesis: 
We hypothesized that disruption in astrocytic IGFR signaling would dysregulate 
astrocyte structure, function and structure and impair cognition in mice. 
Approach 
Aim 1. Examine the effect of IGF-1 signaling on astrocyte functions: glutamate- glutamine 
signaling and release of gliotransmitters 
Hypothesis: We hypothesize that reduction of IGFR signaling will disrupt glutamate 
uptake homeostasis, which is one of the major functions performed by astrocytes. A disruption 
in glutamate handling would in turn affect the glutamate-glutamine cycling inside astrocytes. 
This cycling is critical and tightly regulated as it not only protects neurons from excitotoxicity 
but also is a source of glutamine to neurons. 
Approach: We will culture primary astrocytes from rodent brains, and inhibit IGFR 
pharmacologically and genetically to interfere with the IGFR signaling cascade. We will 
then measure the uptake of glutamate by these astrocytes, assess the availability of 
transporters that take up glutamate, and measure the expression and activity of the various 
components of the glutamate-glutamine cycle. 
Aim 2. Examine the effect of IGF-1 signaling on structure of astrocytes 
Hypothesis: The regulation of structure and function of a cell are intricately related. 
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Here, we hypothesize that deficiency of IGFR signaling would significantly alter the structure 
of an astrocyte by affecting its cytoskeletal proteins like GFAP and Actin. Additionally, it 
would affect the proteins associated with proteins like S100β that contribute to cytoskeletal 
rearrangement in astrogliosis induced by IGFR deficiency. 
Approach: We will culture primary astrocytes from rodent brains, and inhibit IGFR 
pharmacologically to reduce its signaling. We will then assess cytoskeletal proteins like actin 
and GFAP in these astrocytes using immunocytochemistry. We will also assess the expression 
of key proteins involved in regulating the rearrangement and reorganization of astrocyte 
cytoskeleton. 
Aim 3. Examine the effect of astrocyte specific IGF-1 signaling on rodent behavior 
Hypothesis: After knockdown of astrocytic IGFR in mice, we hypothesize that there 
would be an impairment in cognitive function in these mice. Additionally, we also hypothesize 
that the astrocytes in the brains of these animals would be dysfunctional in terms of structure 
and function. 
Approach: We will use the Cre-LoxP system to generate tamoxifen inducible 
astrocyte- specific IGFR knock-out mice (aIGFR-KO) and assess their behavior using several 
behavioral assays including open field test and Rotarod for locomotion and motor 
coordination, grip strength for muscle strength, Radial Arm Water Maze (RAWM) and 
Barnes maze to measure spatial learning and memory, elevated plus maze for anxiety-
measurement, and tail suspension for depression-like measurement. Additionally, we will 
assess the molecular changes in the glutamate-glutamine cycling machinery in these brains 







Figure 1.2. Schematic diagram of the experimental design. In Aim 1, the effect of loss of IGF-1 
signaling on astrocyte function (glutamate-glutamine signaling) will be examined. In Aim 2, the 
effect of loss of IGF-1 signaling on astrocyte structure will be examined. At last, in Aim 3, we 




The innovative aspects of this project include: 1) the hypothesized structural and 
functional regulation of astrocytes by IGF-1 has not been well characterized as most of the 
studies to date have focused on neurons; 2) the proposal uses a unique combination of genetic 
and pharmacological approaches in novel animal models to address the effect of this pathway 
on cognition; 3) these novel models allow us to tease apart the contributions of development 
and the loss of growth signals in adulthood; 4) a better understanding of how IGF-1 signaling 
in astrocytes affects learning and memory will provide a new direction for research and 
therapeutic targeting. Together, these studies will highlight the role of decline in IGF-1 
signaling in regulating the function of astrocytes. 
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CHAPTER 2 INSULIN-LIKE GROWTH FACTOR-1 AND REGULATION 
OF ASTROCYTE FUNCTION 
2.1. Abstract 
Insulin-like Growth Factor-1 (IGF-1) has been studied with respect to its regulation of 
neuronal growth and excitability. Declining levels of IGF-1 have been correlated with 
impaired learning and memory as well as an increased risk of neurodegenerative diseases. 
While neuronal regulation by IGF-1 is well-studied, the role of IGF-1 in influencing the 
function of other brain cell types is not. Along with neurons, astrocytes regulate many aspects 
of the brain microenvironment, including controlling glutamate-glutamine cycling, which 
ultimately supports neuronal metabolism, neurotransmission, and protection from over 
stimulation. 
In this study, we examined whether IGF-1 acts through its cognate receptor, IGFR, to 
alter astrocytic glutamate handling. We utilized both small molecule IGFR inhibitors and Cre- 
driven genetic approaches to reduce IGFR in cultured rodent astrocytes. When IGFR was 
knocked out of primary astrocytes derived from igfrf/f mice using AAV5-CMV-Cre, 
significant reductions in glutamate uptake were observed. Similarly, inhibition of IGFR with 
Picropodophylotoxin for 2 hours, as well as 24 hours, reduced glutamate uptake in vitro. 
Mechanistically, short-term inhibition of IGFR resulted in a significant decrease in glutamate 
transporter availability on the cell surface, as assessed by Biotinylation. Long-term inhibition 
of IGFR led to significant reductions in mRNA expression of glutamate transport machinery, 
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as assessed with qPCR. Interestingly, long-term IGF-1 inhibition also resulted in an increase in 
adenosine triphosphate (ATP)-stimulated glutamate release, though no change in ATP-
stimulated calcium flux was observed nor were any changes in purinergic receptor protein 
expression. Together, these data suggest that reduced IGF-1 signaling will favor an 
accumulation of extra synaptic glutamate, which may contribute to neurodegeneration in 
disease states where IGF- 1 levels are low. 
2.2. Introduction 
Glutamate-Glutamine cycling in the brain 
Glutamate is the major excitatory neurotransmitter in the brain, where it contributes to 
the processes of learning and memory by regulating synaptogenesis, neurogenesis, and 
neuronal excitability (as reviewed by (Shepherd & Huganir, 2007) (Mattson, 1996)). While 
glutamate is important for its excitatory functions, too much glutamate in the extra-synaptic 
milieu can lead to neurotoxicity (Choi, 1988; J. W. Olney, Ho, & Rhee, 1971; John W. Olney, 
1969, 1971; John W. Olney & Ho, 1970). Thus, at any point of time, the steady state 
concentrations of glutamate in the synaptic environment must be tightly regulated. Buffering 
of excess glutamate from the synaptic cleft is achieved with the help of majorly two glutamate 
transporters, EAAT1 and EAAT2 (excitatory amino acid transporter 1 and 2), primarily 
expressed by astrocytes (Kanner & Schuldiner, 1987; Nicholls & Attwell, 1990) (Bröer & 
Brookes, 2001). After EAAT1 and EAAT2 shuttle glutamate into the astrocytes, the glutamate 
is converted to glutamine by glutamine synthetase. Glutamine synthetase is an enzyme only 
expressed in astrocytes. As a result, regulation of astrocytic glutamine synthetase for treating 
neurological disorders has been under focus recently. After conversion, glutamine is then 
released into the synapse for neurons to use for metabolic purposes or as a precursor for 
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additional glutamate neurotransmission. The maintenance of this cycle is crucial as neurons 
cannot make their own glutamine and as a result rely on glutamine supplied by the astrocytes. 
Thus, disruption of this cycle would lead to an accumulation of potentially excitotoxic levels 
of glutamate as well as reduce glutamine availability which would also hamper neuronal 
viability and function (Bak, Schousboe, & Waagepetersen, 2006; Kvamme, Torgner, & 
Roberg, 2001). 
Impaired Glutamate-Glutamine cycling in diseased states 
Reductions in glutamate transport is observed in many pathological disease states, and 
under extreme conditions these transporters are known to reverse their direction of flow and 
cause excess glutamate to be released back into the synaptic space (Malarkey & Parpura, 
2008) (Fontana, 2015). Moreover, swelling of the astrocytes and stimulation with 
extracellular ATP can trigger the release of glutamate to the extracellular space. Increased 
release of glutamate and/or a reduction in EAAT1/2 transport activity is associated with 
several neurodegenerative pathologies, including Alzheimer’s Disease, Huntington’s Disease, 
stroke, and traumatic brain injury (Parpura & Haydon, 2009) (Coulter & Eid, 2012). 
Additionally, a reversal of glutamate transport hinders the availability of glutamine for 
neurons by disrupting the glutamate-glutamine cycle. Unsurprisingly, reduced glutamine 
availability is also a hallmark of several neurological disorders (Coulter & Eid, 2012; T. Eid 
et al., 2004; Tore Eid, Behar, Dhaher, Bumanglag, & Lee, 2012; Tore Eid, Tu, Lee, & Lai, 
2013). 
IGF-1 and Glutamate uptake 
It is intriguing that some of the pathological disease states where glutamate handling 
is impaired are also marked by altered insulin-like growth factor-1 (IGF-1) signaling (Deak 
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& Sonntag, 2012; Markowska, Mooney, & Sonntag, 1998; Vincent, Mobley, Hiller, & 
Feldman, 2004; Wood et al., 2007). IGF-1 is a critical neuroendocrine signaling hormone 
that promotes neurogenesis, synapse formation, and neuronal excitability. Activation of IGF-
1 signaling has been shown to ameliorate some of the pathological effects associated with 
Alzheimer’s Disease, Huntington’s Disease, and age-related cognitive impairment (Bassil, 
Fernagut, Bezard, & Meissner, 2014; Lopes et al., 2014; Moloney et al., 2010; Naia et al., 
2014; Özdinler & Macklis, 2006; Ransome & Hannan, 2013; Rivera et al., 2005; Steen et al., 
2005; Vincent et al., 2004; Westwoo et al., 2014). Moreover, IGF- 1 is also shown to have a 
neuroprotective role in traumatic brain injury and stroke, wherein glutamate excitotoxicity is 
one of the factors that cause neuronal death following insult (Madathil & Saatman, 2015; 
Muir, 2006; Yi & Hazell, 2006).  
Most studies attribute the beneficial effects of IGF-1 on its direct regulation of the 
IGF-1 receptor (IGFR) in neurons. However, astrocytes also express IGFR. Few studies 
have examined the influence of IGF-1 on astrocyte function. Overexpression of an IGF-1 
binding protein, which sequesters IGF-1, was shown to cause significant impairments in 
astrocyte responsiveness following mechanical insult (Rajkumar Brain Research 1997). We 
think astrocytic glutamate handling may also be disrupted with a loss of IGF- 1. We recently 
observed that systemic reduction in liver-produced IGF-1 was associated with a decrease in 
GLT-1 (EAAT2 isoform in rodents) mRNA expression in the cortex of mice (Toth et al., 
2015). Moreover, an in vitro study showed that exogenous IGF-1 upregulates the expression 
of GLAST (EAAT1 isoform in rodents) in cultured astrocytes (Suzuki et al., 2001). It is 
important to note that exogenous IGF-1, such as that used in this previous study, can also 
activate insulin receptors (IR) or heterodimers of IGFR/IR, thus these results must be 
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interpreted with caution as exogenous insulin also produced an increase in GLAST 
expression and function in this study (Suzuki et al., 2001). 
Based on these findings, we hypothesized that IGF-1, acting through its cognate 
receptor IGFR, promotes astrocytic glutamate handling. To test this, we utilized genetic, as 
well as pharmacological inhibition of the IGFR in cultured astrocytes, and examined the 
influence of IGF-1 on the ability of astrocytes to buffer glutamate. Mechanistically, we 
explored the expression of glutamate uptake machinery when IGF-1 signaling is inhibited. 
Together, this study helped us understand how the loss of IGF-1 affects astrocyte-neuron 
microenvironment dynamics, which ultimately influences neuronal viability and cognitive 
function. 
2.3. Materials and Methods 
2.3.1. Animals 
All procedures were approved by and followed the guidelines of the Institutional 
Animal Care and Use Committee at the University of Mississippi. Wild-type Sprague Dawley 
female rats were purchased from Envigo with an estimated pregnancy date of embryonic day 
16-17 upon arrival to the animal facility. The dam was housed until birth when the pups were 
euthanized via rapid decapitation to extract cortical tissue. Tissues from all pups in the litter 
(both males and females) were pooled for in vitro cell culture. Six litters of rats were included 
in this study, with an average of 10-15 pups. The breeder female was euthanized with carbon 
dioxide and subsequent decapitation. Male and female mice homozygous for LoxP sites 
flanking exon 3 of the Igfr gene (mice termed igfrf/f) were purchased from the Jackson 
laboratories and bred in house (strain 012251). Three litters of male and female pups were 
utilized in this study, with an average of 8- 10 pups per litter. Male and female pups were 
26
euthanized via rapid decapitation on post-natal day 1 and cortical tissues from all animals were 
pooled for in vitro cell culture. The breeders were re- entered into our breeding colony after 
pups were removed. All animals were housed with enriched bedding, and provided standard 
rodent chow (5053 Pico Lab, Purina Mills, Richmond, IN) and water ad libitum. Mice were 
housed in SuperMouse750 (12x5.5 inch) ventilated cages, 3-5 per cage, while rats were housed 
in (Ancare R20 10.5x19x8 inch) static cages with a max of 2 per cage. Mice were genotyped 
for the presence of the igfrf/f exon 3 loxp sites. For this, 2-3 millimeter of tails were clipped 
and RNA was extracted using Sigma REDExtract-N-AMP Tissue PCR Kit (XNAT) following 
manufacturer recommendations. The following primers were used for PCR amplification, 
following the recommendations of the Jackson laboratories for thermal cycling for each primer 
set: IGFR forward 5’ CTT CCC AGC TTG CTA CTC TAG G 3’, IGFR reverse 5’ CAG GCT 
TGC AAT GAG ACA TGG G 3’ The resulting PCR product was run on a 1.5% agarose gel 
with Greenglo (Denville CA3600) for one hour at 100V. The gel was imaged and each lane 
was compared to positive and negative controls on the gel. 
2.3.2. Materials 
Insulin-like growth factor 1 (IGF-1) (catalog I3769), picropodophyllotoxin (catalog 
T9576), and ATP (catalog A1862) were purchased from Sigma-Aldrich Chemicals. NVP-
AEW 541 (catalog 13641) was purchased from Cayman chemicals. Radiolabeled glutamate 
(catalog NET490250UC) was purchased from Perkin Elmer, while unlabeled glutamatic acid 
(catalog A1222A) was purchased from ThermoFisher Scientific. 
2.3.3. Astrocyte cultures 
Astrocytes were derived from the cortex and hippocampus of late-stage embryonic or 
early-stage post-natal Sprague Dawley rats or igfrf/f mice, following a previously established 
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protocol (McCarthy & De Vellis, 1980). The cortices and hippocampi of all male and female 
pups in the litters were combined and mixed throughout the culture process. Isolated tissue 
was enzymatically and mechanically digested using papain and trituration, respectively. 
After digestion, cells were resuspended in growth media. For rats, this media consisted of 
Neurobasal medium containing 10% fetal bovine serum, penicillin/streptomycin (10 
units/mL), and Lglutamine (29.2 μg/mL). Mouse astrocyte growth media consisted of 
Dulbecco’s Modified Eagle Medium (DMEM) containing 10% fetal bovine serum, 
penicillin/streptomycin (10 units/mL), Lglutamine (29.2 μg/mL) and N15 supplement 
(Schildge, Bohrer, Beck, & Schachtrup, 2013). Initially, astrocytes were grown in 10cm 
dishes coated with poly-L-lysine. Media was partially changed every three to five days. 
When the cells reached confluence, the plates were shaken to dislodge microglia and 
passaged with trypsin to reduce the presence of other types of cells. This process was 
repeated twice or until neuron number was <5% (as validated with immunocytochemistry). 
2.3.4. Immunocytochemistry of Astrocyte Cultures 
Cultured cells were passaged onto coverslips for immunostaining to determine cellular 
composition. Cells were fixed using 4% paraformaldehyde in phosphate buffer for 10 minutes 
at room temperature. After fixation, they were washed with cold phosphate buffered saline, 
permeabilized with 0.1% TritonX-100 for 10 minutes, and blocked in 1% bovine serum 
albumin, 22.52 mg/mL glycine in phosphate buffered saline with 0.1% Tween 20 for 30 
minutes. The cells were then incubated with polyclonal anti-Glial fibrillary associated protein 
(GFAP) (1:1000 Abcam) in 1% bovine serum albumin overnight at 4 °C. After three washes 
with phosphate buffered saline, secondary Goat Anti-Rabbit IgG (H+L) Secondary Antibody, 
DyLight 650 (1: 10,000 ThermoFisher Scientific) was applied to the coverslips for 1 hour at 
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room temperature. Coverslips were washed in phosphate buffered saline three times and were 
subsequently mounted overnight in Prolong Gold Antifade with DAPI (4′,6-diamidino-2-
phenylindole) mounting media (Molecular Probes). Cells were then imaged at a magnification 
of 200X using a Nikon Ti-2 inverted microscope. 93% of cells were GFAP+ 
2.3.5. Knock-down of IGFR in igfrf/f astrocyte cultures 
To genetically reduce IGFR in astrocytes, astrocyte cultures were derived from igfrf/f 
mice (described above) and transduced with AAV5-CMV-Cre or control AAV5-CMV-GFP. 
Block randomization was utilized to assign treatment groups to the cultures. Purified viral 
vectors were purchased from Penn Vector Core. The viruses were diluted 1:10,000 in cell 
growth media and administered 72-86 hours prior to cell testing experiments. Knock-out of 
exon 3 was validated using qPCR (described below). 
2.3.6. Cell death assays 
Cell viability was measured using ethidium homodimer, calcein-AM, and DAPI cell 
counting. Mouse astrocytes were transduced with viral vectors as described, and viability was 
assessed in these cells following ethidium homodimer application to label cells with 
compromised membranes and DAPI staining to count total nuclei. FITC labeled Calcein AM 
was avoided in this assay as our control virus (AAV5-CMV-GFP) was FITC+. For cells 
treated with picropodophillyotoxin (PPP), the coverslips were washed in phosphate buffered 
saline and stained using Live/Dead Cytotoxicity/Viability kit (Molecular Probes) as per the 
manufacturer’s protocol. Each coverslip was imaged in three different fields using TRITC 
filter to detect ethidium homodimer+ cytotoxic cells with compromised cell membranes, and a 
FITC filter to detect calcein-AM cleaved FITC+ (metabolically-active) cells on a Nikon Ti-2 
inverted microscope at a magnification of 200X. Cells were quantified using the automated 
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counting software Nikon Elements 3.0 as previously described (Ashpole & Hudmon, 2011). 
Total cell number was determined by addition of cytotoxic and viable cells. 
2.3.7. Glutamate uptake assays 
Radiolabeled glutamate uptake assays were performed as described previously (Ashpole 
et al., 2013). Following treatment, cells were washed with ice-cold phosphate buffered saline 
and subsequently stimulated with growth media containing 1 μg/ml [3H]-glutamate (Perkin 
Elmer) and 100 μM unlabeled glutamate for varying lengths of time at 37 °C. The treatments 
(with drug and with glutamate) were assigned with block randomization in which all doses or 
time points had equal n. The cultures were then washed in ice-cold phosphate buffered saline by 
a researcher blinded to the treatment groups, lysed in 200 mM NaCl, 0.1 mM EGTA, 20 mM 
Tris HCl pH 7.4, mixed, and diluted in 3 mL RadSafe liquid scintillation fluid (Beckman 
Coulter). [3H]- Glutamate within the lysates was quantified using a Beckman liquid scintillation 
counter. 
2.3.8. Biotinylation of cell surface proteins 
Cell surface biotinylation was carried out using the Pierce Cell Surface Protein 
Isolation Kit (Catalog number: 89881) following manufacturer's instructions. Primary 
astrocyte cultures were grown in T-75 flasks. When 100 percent confluent, the cells were 
treated with 5 μM PPP or DMSO. After 2 hours, the media was discarded. The cells were 
washed twice with ice-cold phosphate buffered saline, and then incubated at 4°C with 
sulfosuccinimidyl-2-(biotinamido) ethyl-1,3- dithiopropionate (Sulfo-NHS-SS-biotin; Pierce) 
on a rocking platform for 30 minutes. After quenching the excess biotin with quenching 
solution, astrocytes were gently lysed with a cell scraper and centrifuged at 2000 x g for 5 
minutes. The supernatant was discarded, the pellet was washed and lysed with 500 μL of lysis 
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buffer and centrifuged at 10,000 x g for 2 minutes at 4°C. The supernatant was then added to 
immobilized NeutrAvidin gel slurry in columns (Pierce). These columns were washed and 
protein elution was carried out using LDS buffer containing DTT for 1 hour at room 
temperature. EAAT1 and EAAT2 proteins were probed using SDS- PAGE gel electrophoresis 
using the following antibodies: Rabbit polyclonal anti-EAAT1 antibody (Abcam; ab416, 
1:1000) and Rabbit polyclonal anti-EAAT2 antibody (Abcam; ab41621, 1:1000) and IRDye 
800CW Goat anti-Rabbit IgG secondary antibody. Anti-GAPDH antibody (Abcam; ab8245, 
1:1000) was used as the loading control for normalizing the levels of EAAT1 and EAAT2. 
2.3.9. Western Blotting 
Tissue was lysed and sonicated in 200 μL of RIPA buffer. Protein was quantified using  
DC protein assay kit (Biorad, Catalog number-5000112) following manufacturer’s protocol. 
Samples were loaded at random by a blinded experimenter, run on a 10% Bis-tris gel with 
MOPS buffer, transferred at 30 volts for one hour using the XCell SureLock transfer system. 
Western blotting was performed using the following primary antibodies: Rabbit polyclonal 
Anti- P2Y4 Antibody- PA5-51032 (1:1000), P2Y1 Antibody (E-1): sc-377324 (1:500), and 
P2X7 Antibody (D-1): sc- 514962 (1:500). GAPDH was used as the loading control. 
Secondary antibodies used were IRDye 680RD Goat anti-Rabbit and Goat anti-mouse. 
Imaging was done using a LI-COR/Odyssey imaging station. 
2.3.10. Measurement of glutamate release 
Twenty-four hours after treating the astrocytes with the pharmacological 
agonists/antagonists described, the extracellular media was analyzed for presence of 
glutamate using Amplex red glutamatic acid assay kit (Thermo Fisher Scientific), as per 
manufacturers guidelines. In addition to basal measurements, astrocytes were stimulated 
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with 200 μM adenosine triphosphate (ATP) to instigate glutamate release. 15 minutes after 
ATP stimulation, extracellular media was taken and analyzed using Amplex red glutamate 
assay kit. 
2.3.11. Calcium Imaging 
Astrocytes were grown in 96 well plates. At complete confluency, they were treated 
with 5 μM PPP or DMSO. 24 hours after the treatment, the media was removed, cells were 
washed with phosphate buffered saline and then loaded with a solution of 7.5 μM Fluo 4 AM 
(Invitrogen) in phosphate buffered saline. After one hour, the solution was taken off, cells 
were washed 3 times with ice cold phosphate buffered saline and placed in Hanks Balanced 
Salt Solution for imaging. Cells were imaged every ten seconds using a Nikon Ti-E inverted 
microscope with a FITC filter. Two minutes into the imaging, the cells were stimulated with 
200 μM ATP (Sigma) and recorded for 10 minutes. Analysis was performed using Nikon 
Elements analysis software and Fluo-4 levels were measured in 30 cells in each well, and 4 
such wells were imaged. The fluorescent intensity of each cell was normalized to the baseline 
(until 2 minutes) before stimulation with ATP. 
2.3.12. Gene expression 
Following treatment, astrocyte cultures were harvested to examine changes in mRNA 
expression. Treatment media was aspirated, cells were washed with ice-cold phosphate 
buffered saline, and total RNA was isolated using the RNAeasy mini kit (Qiagen). cDNA was 
made using High- Capacity RNA-to-cDNA kit (Applied Biosystems). RT-PCR was 
performed using TaqMan Universal PCR Master mix (Life Technologies) and TaqMan 
validated primers on the CFX Connect Real time PCR detection system (Bio-Rad). Results 
were normalized to the housekeeping gene HPRT. Knock-down of igfrf/f was also assessed 
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using RT-PCR with readily available TaqMan primers targeting exon 3. 
2.4. Statistical Analysis  
Experiments were designed considering statistical power and sample size estimation. We have 
set β at 0.8 and α at 0.05. Based on pilot studies in our laboratory, we are able to estimate the baseline 
variability and determine most of the in vitro studies require sample sizes of 5-6, although release 
assays had higher variability and may require at least 12 replicates. Statistical analysis was performed 
using SigmaPlot v13 software. One-way ANOVAs and Two-way ANOVAs with subsequent 
Dunnett’s or Tukey’s tests were used to compare difference between groups, as determined 
appropriate for comparison. When appropriate, a Student's t test was also performed. This study was 
not pre-registered. 
2.5. Results 
2.5.1. Glutamate uptake in IGFR deficient astrocyte cultures 
Glial fibrillary acid protein (GFAP) positive astrocytes cultures were derived from 
igfrf/f mice. Transduction of these cells with AAV5-CMV-Cre resulted in an 82% reduction in 
the expression of exon 3 of IGFR compared to cells transduced with control AAV5-CMV-
GFP, as assessed with qPCR (Figure 2.1 A). Exon 3 was targeted as it is responsible for the 
ligand-binding and activation of IGFR. No significant changes in the expression of common 
astrocyte markers, GFAP, aquaporin-4 (AQ4), and aldehyde dehydrogenase 1, L1 
(ALDH1L1) were observed following IGFR knockdown. A trending decrease in IGF-1 
mRNA was observed when IGFR was reduced, however this difference was not significant 
(p=0.062). Despite this reduction in IGFR, no change in cell viability was observed with 
AAV5-CMV-Cre treatment (Figure 2.1B). Glutamate uptake was then assessed using a well-
established radiolabeled glutamate assay (Ashpole et al., 2013). When [3H]-glutamate was 
applied to astrocyte cultures for varying amounts of time, a reduction in uptake was observed 
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in the IGFR-deficient astrocytes (AAV5- CMV-Cre treated) compared to control (AAV5-
CMV-GFP treated) (Figure 2.1C). While this impairment in glutamate uptake was not present 
at 5 minutes, it was statistically significant at 10, 20, and 30 minutes (Figure 2.1C). 
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Figure 2.1 Glutamate uptake is reduced in cultured IGFR deficient astrocytes. (A) mRNA 
levels of IGF-1 signaling genes and astrocyte markers genes after IGFR was knocked down in 
igfrf/f astrocytes using AAV-CMV-Cre or control AAV-CMV-GFP (The data are expressed as 
mean±SE of 6-12 replicate samples, *denotes p< 0.05). (B) Representative images of control 
and IGFR deficient astrocytes labeled with ethidium homodimer and DAPI (captured at a 
magnification of 100x). Total cell number and % living cells per field have been quantified 
(The data are expressed as mean±SD of 5 independent cover slips and a total of 15 fields). (C) 
Uptake of [3H]-glutamate over time in controls and IGFR deficient astrocytes (The data are 
expressed as mean±SE of 5 independent replicate samples per time point, * denotes p<0.05, 
two-way ANOVA, post-hoc Tukey’s test). 
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Pharmacological inhibition of IGFR induces long-term impairments in glutamate uptake 
To better understand this reduction in glutamate uptake when IGFR is reduced, 
pharmacological antagonists of IGFR were administered to cultured astrocytes and glutamate 
uptake was subsequently assessed. Based on preliminary studies, we determined that 20 
minutes of [3H]- glutamate treatment was sufficient to reach peak glutamate uptake. This 
incubation period was used to assess glutamate uptake after treating the astrocytes with 
exogenous IGF-1 and 2 different IGFR inhibitors. IGF-1 significantly increased glutamate 
uptake 24 hours after application (Figure 2.2A). Conversely, treatment with 
picropodophyllotoxin (PPP) and NVP- AEW 541, small molecule inhibitors of the 
downstream IGFR kinase activity, resulted in a significant reduction in glutamate uptake 24 
hours after application compared to control (Figure 2.2A). Astrocytes were then treated with 
varying concentrations of PPP to assess the concentration response relationship between IGF-
1 inhibition and impaired glutamate uptake. A significant decrease in uptake 24 hours after 
treatment was observed at concentrations greater than 1 μM PPP (Figure 2.2B). Similar to 
other reports of PPP potency in cells, the IC50 of PPP in the glutamate uptake assay was 0.32 
μM. This concentration-response curve was assessed following 20 minutes of incubation with 
[3H]-glutamate. The kinetics of glutamate uptake following long-term pharmacological IGFR 
inhibition with PPP revealed a significant decrease in uptake after 10 minutes and remained 
significantly lower than vehicle-treated cells throughout the remaining time points (Figure 
2.2C). 
IGFR inhibition leads to decreased glutamate transporter machinery 
We explored whether IGF-1 inhibition resulted in changes in glutamate transporter 
mRNA expression. IGFR inhibition with PPP resulted in a significant decrease in EAAT1 
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(GLAST), EAAT2 (GLT1), and glutamine synthetase (GS) expression 24 hours later 
(Figure 2.2D). We also examined changes in these genes following addition of 250 nM of 
exogenous IGF-1 and saw no change. Considering this discrepancy between exogenous 
IGF-1 and the IGFR inhibitor, PPP, we examined the expression of the glutamate handling 
machinery in the igfrf/f cultures treated with AAV5-CMV-Cre or control AAV5-CMV-
GFP. A 24% decrease in EAAT1 was observed, as well as a 38% decrease in EAAT2, and 
a 32% decrease in glutamine synthetase when IGFR was genetically reduced (Figure 
2.2.E). 
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Figure 2.2. Long-term inhibition of IGFR signaling alters glutamate uptake (A) Average 
glutamate uptake after 20-minute glutamate stimulation in cultured astrocytes treated with 5 μM 
PPP, 3.3 μM NVP-AEW541, 250nM exogenous IGF-1, or DMSO vehicle. The * indicates a 
significant difference in comparison with control, while the # with IGF-1 treated astrocytes. 
(The data are expressed as mean±SE of 5 replicate samples per group, One-way ANOVA, post-
hoc Dunnett test, *#p< 0.05). (B) PPP concentration response curve on glutamate uptake. The * 
indicates significant differences in comparison with control (The data are expressed as mean±SE 
of 5 replicate samples per group, One-way ANOVA, post-hoc Dunn’s, *p< 0.05). (C) Change in 
glutamate uptake kinetics with 24-hour treatment with 5 μM PPP. The * indicates a significant 
difference in comparison with DMSO treated group (The data are expressed as mean±SE of 5 
replicate samples, Two-way ANOVA, post-hoc Dunnett’s test, *p< 0.05). (D) Relative mRNA 
expression of glutamate uptake transporters EAAT1, EAAT2 and glutamine synthetase (GS) 
respectively in response to 24-hour treatment with 5 μM PPP or 250 nM IGF-1. The * indicates a 
significant difference in comparison with controls (The data are expressed as mean±SE  of  8-
10  biological  replicate  samples,  One-way  ANOVA,  post-hoc  Dunnett’s test, *p<0.05). (E) 
Relative mRNA expression of EAAT1, EAAT2 and glutamine synthetase (GS) respectively in 
control and IGFR deficient astrocytes. All data were normalized to HPRT. The * indicates a 
significant difference between control and IGFR deficient astrocytes (The data are expressed as 
mean±SE of 5-6 biological replicate samples, t-test, *p<0.05) 
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Short-term IGFR inhibition also decreases glutamate uptake by reducing EAAT1 availability 
To determine whether glutamate uptake was impaired with short-term inhibition of 
IGFR, PPP was administered (5 μM) to the astrocytes for two hours and glutamate uptake was 
then examined. A significant reduction in glutamate uptake was observed following two hours 
of PPP exposure (Figure 2.3A). This short-term functional change was not accompanied by a 
decrease in EAAT1 or EAAT2 expression (Figure 2.3B), nor significant changes in protein 
expression (Figure 2.3C). However, biotinylation of cell surface proteins highlighted a 
significant decrease in surface availability of EAAT1 (Figure 2.3D). These data suggest that 
short-term and long- term changes in glutamate uptake are induced by the inhibition of IGF-1, 




Figure 2.3. Short-term Inhibition of IGFR signaling interferes with glutamate uptake by altering 
the trafficking of glutamate uptake machinery. (A) Change in glutamate uptake kinetics in 
response to a short-term treatment with 5 μM PPP for 2 hours. The * indicates a significant 
difference as compared with the controls. (The data are expressed as mean±SE of 5 biological 
replicates per time point, t-test to compare ppp to dmso at that time point, *p< 0.05). (B) 
Relative mRNA expression of transporters EAAT1, EAAT2 and Glutamine synthetase in 
response to a 2- hour treatment with PPP or DMSO. All data are normalized to DMSO. (The 
data are expressed as mean±SE of 8-10 biological replicates per group, One-way ANOVA, 
post-hoc Tukey’s test). (C) Relative expression of transporters EAAT1 and EAAT2 proteins in 
response to a 2-hour treatment with PPP or DMSO. All data are normalized to GAPDH. (The 
data are expressed as mean±SE of 5-6 biological replicates per group, t-test) (D) Trafficking of 
transporters EAAT1 and EAAT2 to the cell surface in response to a 2-hour treatment with PPP 
or DMSO. All data are normalized to Na+K+ATPase. The * indicates a significant difference as 
compared with DMSO treated cells. (The data are expressed as mean±SE of 4 replicates, t-test, 
p<0.05) 
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2.5.2. Glutamate release with inhibition of IGF-1 
Considering the impaired glutamate uptake within the cultures, we also assessed 
whether basal glutamate levels within the cell culture media were altered by IGF-1 inhibition. 
No significant changes in the basal extracellular glutamate concentrations following 24 hour 
PPP treatment were observed (Figure 2.4 A), nor were any changes observed when IGF-1 was 
administered to the astrocytes (data not shown). To test whether the ability of astrocytes to 
release glutamate in response to stimulation was altered, we stimulated the astrocytes with 200 
μM ATP and measured extracellular glutamate levels. In control cells, stimulation with ATP 
resulted in an increased amount of glutamate in the media. Addition of IGF-1 did not alter 
ATP-stimulated glutamate release (Figure 2.4B); however, PPP treatment resulted in a 
concentration-dependent increase in extracellular glutamate (Figure 2.4A-B). At 
concentrations of 1.25 μM and above, glutamate release was significantly higher than control. 
To determine whether this increased glutamate release was a consequence of significant 
changes in purinergic responsiveness, we measured intracellular calcium levels in astrocytes 
treated with PPP and subsequently stimulated with 200 μM ATP. Consistent with prior studies, 
ATP stimulation led to a rapid increase in intracellular calcium (Figure 2.4C). However, there 
was no difference in ATP-response between PPP or vehicle treated cells (Figure 2.4C). 
Furthermore, there was no significant difference in the protein levels of purinergic receptors 
P2Y1, P2Y4, or P2X7 in astrocytes treated with PPP (Figure 2.4D). 
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Figure 2.4. Increased ATP-stimulated glutamate release in response to inhibition of IGFR (A) 
Average glutamate levels under basal or stimulated conditions (with 200 μM ATP for 10 
minutes) after a 24-hour treatment with different concentrations of PPP as indicated, 
normalized to DMSO. The * indicates significant difference vs 0μM while the # indicates 
significant difference between basal and ATP-stimulated glutamate at that concentration of 
PPP. (B) Average levels of glutamate in the media after a 24-hour treatment with 5 μM PPP, 
250 nM IGF-1, or DMSO followed by stimulation with 200 μM ATP for 10 minutes. In both 
(A) and (B), the * indicates a significant difference in comparison with controls (The data are 
represented as mean±SE of 3 technical replicates, 6 biological replicates (n=18), One-way 
ANOVA, post-hoc Dunnett’s test, *p<0.05). (C) Calcium signaling using 7.5 μM Fluo 4AM 
under stimulated conditions (with 200 μM ATP) after a 24-hour treatment with 5 μM PPP or 
250 nM IGF-1. All the data are normalized to baseline (The data are expressed as ±SE of 4 
wells with 30 cells per well, one-way ANOVA). (D) Relative expression of purinergic 
receptors’ P2Y1, P2Y4 and P2X7 proteins in response to a 24-hour treatment with 5 μM PPP 
or DMSO. All data are normalized to GAPDH. (The data are expressed as mean±SE of 6 
biological replicates per group, t-test) 
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2.6. Discussion 
An imbalance of glutamate in the synapse leads to excitotoxicity, which has been 
implicated in a number of neurological disorders like stroke, traumatic brain injury, and aging, 
as well as neurodegenerative disorders like Alzheimer’s disease, Parkinson’s disease, 
Huntington’s disease and ALS (Arundine & Tymianski, 2004; Ashpole & Hudmon, 2011; 
Coyle & Puttfarcken, 1993; Lau & Tymianski, 2010; Muir, 2006; Toth et al., 2015). 
Interestingly, a perturbation in IGF-1 signaling is also observed in these disorders. Agonists of 
IGFR have been shown to be beneficial in animal models of Huntington’s Disease, age-related 
cognitive impairment, stroke, and traumatic brain injury (Bassil et al., 2014; Lopes et al., 2014; 
Moloney et al., 2010; Naia et al., 2014; Özdinler & Macklis, 2006; Ransome & Hannan, 2013; 
Rivera et al., 2005; Steen et al., 2005; Vincent et al., 2004; Westwood et al., 2014; Madathil & 
Saatman, 2015; Muir, 2006; Yi & Hazell, 2006). While there remains controversy regarding 
the role of IGF-1 in Alzheimer’s Disease pathology, a nearly 80% decrease in the expression of 
IGFR and IGF-1 has been observed in human Alzheimer’s Disease brain tissue (Steen et al., 
2005; Rivera et al., 2005). 
Moreover, several studies have suggested that Alzheimer’s Disease is marked by an 
increased resistance to IGF-1 (Moloney et al., 2010; Talbot et al., 2012), which emphasizes 
the importance for examining the effects of reduced IGF-1 signaling in the adult brain. 
Clinical trials have yet to show efficacy of exogenous IGF-1 treatment in humans; however, 
evidence shows a strong inverse relationship between IGF- 1 levels and the risk/severity of 
many of these excitotoxic diseases in humans (Aleman et al., 1999; Dong, Chang, Ji, Tao, & 
Wang, 2014; Tumati, Burger, Martens, Van Der Schouw, &Aleman, 2016; (Aberg et al., 
2019). In vitro testing has highlighted the neuroprotective capabilities of IGF-1 against insults 
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like excitotoxicity and oxidative stress. Exogenous IGF-1 protects cultured rodent and human 
neurons from excitotoxic levels of gluamate, amyloid-beta, H2O2, and inflammation (Genis et 
al., 2014; Trejo, Carro, & Torres-Alemán, 2018; Alcedo & Kenyon, 2004; Brooker et al., 
2000; Dudek et al., 1997; Gazit et al., 2016; Özdinler & Macklis, 2006; Xing et al., 2007). 
Interestingly, overexpression of IGF-1 in astrocytes is capable of protecting nearby 
neurons from oxidative stress, which was thought to be due to the release of IGF-1 from the 
astrocytes to act on nearby neurons in a paracrine manner (Madathil et al., 2013). 
Additionally, release of IGF-1 from astrocytes also protects neurons from amyloid-beta 
toxicity (Pitt et al., 2017). Our study did not focus on the effects of IGF-1 produced in the 
astrocytes; rather, it examined the effects of IGF-1 on the astrocytes. Past evidence has 
suggested the role of IGF-1 in regulating astrocyte glutamate handling. 
Treatment of cultured astrocytes with exogenous IGF-1 transiently increased the 
expression and function of glutamate transporters (Suzuki et al., 2001). Interpretation of 
mechanistic studies using exogenous IGF-1 can be difficult, as IGF-1 also activates the insulin 
receptor (IR) and codimers of IGFR/IR. Indeed, that same study highlighted a similar transient 
increase in glutamate transporter expression and function with exogenous insulin treatment. To 
circumvent this limitation and directly assess whether IGF-1 acts through its cognate receptor 
to promote glutamate handling, we utilized a combination of pharmacological and genetic 
tools to decrease IGFR activation and examined the consequences on glutamate handling. 
Genetic inhibition, as well as pharmacological inhibition at multiple levels in the IGFR 
signaling pathway, resulted in a significant reduction in glutamate uptake. These data verify 
the previous literature findings, suggesting IGF-1 promotes astrocytic glutamate uptake 
(Suzuki et al., 2001) and emphasize the importance of the IGF-1 receptor. 
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A few other recent studies have utilized this inhibitory approach to explore the role of 
IGF-1 in regulating other aspects of astrocyte function. Antagonism of IGFR using a 
monoclonal antibody decreased the ability of astrocytes to protect neurons from oxidative 
stress (Genis et al., 2014; Ratcliffe et al., 2018). This study by Ratcliffe et al. also showed that 
inhibition of IGFR did not alter the neurotrophic support provided by astrocytes, as no change 
in neurite outgrowth was observed in neurons co-cultured with IGFR deficient astrocytes. A 
genetic reduction in astrocytic IGFR was also shown to impair amyloid beta sequestration and 
glucose uptake (Logan et al., 2018). In combination with these studies, we provide evidence 
that IGF-1 is an important regulator of astrocytic glutamate handling. 
In order to investigate the mechanism of the impaired glutamate uptake, we looked for 
changes in cell viability, glutamate transporter expression, and cell surface availability of the 
glutamate transporter. No changes in viability were noted. We observed that in response to 
IGFR antagonism, there is a decrease in mRNA levels of both the transporters, EAAT1 and 
EAAT2, in cultured astrocytes. Short-term inhibition of IGF-1 signaling led to a significant 
decrease in EAAT2 availability within the membrane of cultured astrocytes. We also saw a 
paradoxical decrease in EAAT1 expression following IGF-1 stimulation in these cells. The 
goal of our exogenous IGF-1 treatment was to verify the increased EAAT2 expression noted 
in the Suzuki study (Suzuki et al., 2001). However, we saw no significant change in EAAT2 
expression and a significant decrease in EAAT1 expression when extra IGF-1 was added to 
the cells. The time point in which mRNA expression was assessed did vary between studies, 
but we do not have a ready explanation for how exogenous IGF-1 would decrease EAAT1. 
We observed significant increases in ATP-stimulated glutamate release from astrocytes treated 
with IGFR inhibitors. ATP activates the metabotropic P2Y receptors on astrocytes and causes 
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the release of glutamate via elevated intracellular calcium levels (Duan et al., 2003). 
Unfortunately, we did not detect any changes in intracellular calcium or expression of 
purinergic receptors. 
Future studies may want to further explore a mechanism for the increased glutamate 
release as there are several other proteins/pathways that can induce the release of glutamate 
from astrocytes, as reviewed by (Malarkey & Parpura, 2008). The reversal of glutamate 
transporters is another potential mechanism for glutamate release (Szatkowski, Barbour, & 
Attwell, 1990). This reversal may explain the bell-shaped curve in glutamate uptake observed 
in our long-term radioligand experiment, in which glutamate uptake was lower at 2 hours post 
incubation with the ligand than at 60 minutes. However, this would require further 
investigation as glutamate transporter reversal is thought to be limited to extreme pathological 
conditions marked by energy imbalance (Fontana, 2015; Grewer et al., 2008). Interestingly, 
cells treated with both the vehicle control and IGF-1 inhibitor, PPP, showed this reduction at 
the 2-hour time point, suggesting a phenotypic change in glutamate handling that IGF-1 does 
not directly regulate. Calcium-induced exocytosis, which is also believed to be the 
predominant mechanism for glutamate release under physiological conditions (Parpura et al., 
1994), the presence of unpaired connexons (Ye, Wyeth, Baltan-Tekkok, & Ransom, 2003), 
swelling of astrocytes and opening of voltage regulated anion channels (VRACS) (Pang, 
Goderie, Higman, Kimelberg, & Waniewski, 2018), and release of glutamate in exchange of 
cysteine by cysteine-glutamate antiporter (Warr, Takahashi, & Attwell, 1999) are other 
mechanisms by which glutamate is released from astrocytes. We did not examine these other 
mechanisms directly, and it may be relevant to determine whether IGF-1 deficiency supports 
the release of glutamate through these avenues in the future as well. 
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Conclusion 
In conclusion, IGF-1 signaling through IGFR promotes glutamate uptake in astrocytes 
by stabilizing expression and availability of the glutamate transporters. The loss of IGF-1, as 
seen in many neurodegenerative disease states, would lead to impaired glutamate uptake and 
enhanced glutamate release from astrocytes, which would preferentially generate an 
excitotoxic environment. Moreover, the reduction in glutamate uptake would likely also lead 
to impaired glutamine cycling, which is important for neuronal metabolism and 
neurotransmission. Thus, a better understanding of how astrocytic IGFR deficiency alters 
neurodegeneration in vivo is now needed in future studies. 
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CHAPTER 3. IGF-1 REGULATION OF ASTROCYTE STRUCTURE 
Abstract 
S100β is a calcium-binding protein belonging to the family of S100 proteins 
predominantly expressed in astrocytes. This protein is implicated in several neurological 
disorders and serves as a biomarker. One of its several functions include regulation of shape 
and migration of astrocytes by stimulation of Rho-ROCK and PI3K/Akt pathways in astrocytes. 
It is known that IGF-1 acts on astrocytic IGFR to initiate signaling through the canonical 
PI3K/Akt pathways. IGF-1 influences various functions in astrocytes, however, not much is 
known about the influence of loss of IGF-1 signaling on the structure of astrocytes. Since the 
structure of a cell is intricately connected to its function, we examined whether loss of IGF-1 
alters the structure of astrocytes by rearrangements in actin cytoskeleton via modulating S100β 
expression or localization. For this, we treated cultured astrocytes with a pharmacological 
inhibitor of IGFR and assessed changes in cytoskeletal protein actin, as well as the expression 
of proteins involved in mediating these cytoskeletal changes. We did not observe a significant 
change in any of these proteins. The data obtained from this study indicates that loss of IGF1 
signaling does not alter the structure of astrocytes via the Rho/ROCK and PI3K/Akt pathways. 
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3.1. Introduction 
S100β is a calcium-sensing protein belonging to the family of S100 proteins, a family 
characterized by the presence of EF-hand binding motifs. S100 proteins are small proteins with 
two EF hands (each constituted by Helix E, Helix F and a loop connecting them), a central hinge 
region and two N and C termini. They exhibit a high degree of homology to each other due to 
their amino acid sequences (Brodersen et al., 1998; Heizmann et al., 2002; Kawasaki & 
Kretsinger, 2014). S100 proteins were named so because of their solublity in 100 % saturated 
ammonium sulphate at pH 7 (Moore BW, 1965). While the genes encoding majority of S100 
proteins are located on chromosomal region 1q21, the gene coding for S100β is located on 
chromosomal region 21q22. Despite the absence of any inherent catalytic activity, these proteins 
bind to calcium ions and undergo a conformational change. This reveals the hydrophobic cleft 
which then binds to a wide range of effector proteins that may be involved in one or more 
functions including cell growth and differentiation, proliferation, migration, apoptosis, and 
protein phosphorylation (Donato, 1986, 1999; Friel et al., 2007). This family has about 25 
different proteins expressed at varying concentrations in various cell types both in the CNS and 
outside it (as reviewed in (Michetti et al., 2019)). 
Although S100β is predominantly expressed in astrocytes, it is also expressed in small 
amounts in Schwann cells and oligodendrocytes in the brain under physiological conditions. 
Additionally, it is also expressed in non-neural tissues like the myocardium under certain 
pathological conditions involving the loss of regulatory factors (Daffu et al., 2013; Riuzzi et al., 
2011; Tateishi, et al., 2006). S100β can be released by glial cells or leaks out from damaged 
cells where it acts as an extracellular apoptotic signal by serving as a protein associated with 
damage-associated molecular pattern (Ahlemeyer et al., 2000). It acts both as an intracellular 
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regulatory protein and an extracellular signal (Sorci et al., 2011; Van Eldik & Wainwright, 
2003). 
Alterations in the levels of S100β is implicated in several neurological disorders 
including include ischemic stroke, traumatic brain injury, neurodegenerative disorders like 
Alzheimer’s disease (AD), Amyotrophic Lateral Sclerosis (ALS), Parkinson’s disease (PD), 
migraine, Multiple Sclerosis, Down Syndrome, schizophrenia and several mood disorders (as 
reviewed in (Michetti et al., 2019)). Interestingly, several studies in animals as well as humans 
have shown that S100β expression is elevated in neurodegenerative disorders at the site of 
damage. For example, in Alzheimer’s disease (AD), S100β protein levels are found to be 
upregulated in areas of amyloid beta deposition, and interfibrillary tangles of tau protein (Chow 
et al., 2010; Cristóvaõ & Gomes, 2019; J.G. et al., 2000; Mrak et al., 1996; Peskind, et al., 2001; 
Van Eldik & Griffin, 1994; W.S.T. et al., 1989). In Parkinson’s disease (PD), levels are elevated 
in substantia nigra pars compacta, a region of the brain where loss of dopaminergic neurons is 
seen (Sathe et al., 2012; Viana et al., 2016). Additionally, S100β levels are high in the cortex 
and spinal cord in ALS (Rydbirk et al., 2017; Serrano et al., 2017). Similarly, in inflammatory 
diseases like Multiple Sclerosis, expression is increased wherever demylination occurs 
(Grygorowicz et al., 2016; Petzold, 2002). In stroke and brain injury levels of S100β are 
elevated in hippocampus and the entire affected hemisphere (Sandhir et al., 2008; Tateishi et 
al., 2002). 
Intriguingly, in schizophrenia and some other mood disorders some studies suggest 
that S100β expression is downregulated (Gattaz et al., 2000; Hong et al., 2016), while in others 
it is upregulated (Zhang et al., 2010). Despite its non-specificity and involvement in multiple 
diseased states, it is still considered as a biomarker for a number of diseases. Levels of S100β 
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in cerebrospinal fluid (CSF), serum and other body fluids like saliva, urine, and perinatal fluid 
are often used as indication of the severity of disease (Gazzolo et al., 2005, 2004; Michetti et 
al., 2012; Michetti & Gazzolo, 2002). The involvement of S100β in so many neurological 
disorders at the site of damage suggests that it may be serving either a protective or a 
proinflammatory role. 
Interestingly, S100β can elicit a toxic or a trophic effect and this Jekyll and Hyde like 
role of S100β can be attributed to its concentration at the site of action (Donato et al., 2009). At 
picomolar or nanomolar concentrations, it is known to exert a trophic role, while at micromolar 
concentrations, it is known to exert toxicity. Some of the trophic effects of S100β include release 
and regulation of growth factors, neurite outgrowth, neuron survival and growth, reducing 
oxidative stress, activation of anti-apoptotic proteins like Bcl-2, ameliorating neurotoxic effects 
and influencing long-term potential in neurons (Ahlemeyer et al., 2000; Bernardini et al., 2010; 
Bhattacharyya et al., 1992; Businaro et al., 2006; Clementi, et al., 2013; Donato et al., 2009; 
Clementi, et al., 2016; Haglid, et al., 1977; Kligman & Marshak, 1985; Nishiyama et al., 2002; 
Reali et al., 2012). Additionally, it also promotes proliferation of glia (Selinfreund et al., 1991). 
Thus, the concentration of S100β is very crucial not only for maintaining the functions of 
neurons, but also glial cells. At micromolar concentrations, the toxic effects occurring include 
oxidative stress, mitochondrial dysfunction, triggering of apoptotic pathways and mediation of 
proinflammatory pathways (Donato et al., 2009; Fujiya et al., 2014; Hosokawa et al., 2017; 
Niven et al., 2015; Piazza et al., 2013). Most of these toxic effects are mediated by activation of 
a transmembrane receptor called Receptor for advanced glycation endproducts (RAGE) by 
S100β, causing astrocytes to become reactive and release more of S100β, thereby activating an 
autocrine loop, ultimately leading to inflammation and neurodegeneration in the brain (Huttunen 
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et al., 2000; Lasič et al., 2016; Villarreal et al., 2014). S100β also interacts with the basic 
fibroblast growth factor (bFGF)/FGF growth factor receptor and act as a mitogen. A number of 
factors determine whether it acts via the RAGE or FGF growth factor receptor. These include 
the concentration of S100β, the expression and availability of FGF, and the requirement of the 
cell at the time (Riuzzi et al., 2011). In microglia, RAGE regulation by S100β activates 
chemokine receptors leading to an neuroinflammatory response (Bianchi et al.,2011). Thus, 
astrocytic S100β may play a crucial role in regulating the response of glial cells in 
neuroinflammation and neurodegeneration. 
In addition to interacting with various extracellular ligands, S100β also interacts with a 
number of intracellular proteins, thereby initiating a number of signaling cascades facilitating 
the communication between cells in response to a physiological or pathophysiological event 
(Bongarzone et al., 2017). As an intracellular signal, it is involved in the phosphorylation of 
some important proteins like tau, while inhibiting the phosphorylation of others like GFAP, and 
p53 (Fernandez et al., 2005; Lin et al., 2004; J. Van Dieck et al., 2010; J. Van Dieck et al., 2009). 
S100β also regulates cognitive flexibility by modulation of calcium binding dynamics (Brockett 
et al., 2018). Additionally, it plays a role in influencing the shape and migration of astrocytes 
under physiological and pathophysiological conditions by regulating the cytoskeletal 
rearrangement through the disassembly of Type III intermediate filaments, tubulin filaments, as 
well as actin rearrangement (Baudier & Cole, 1988; Brozzi, et al., 2009).  
A reduction in the expression of S100β in astrocytes causes an increase in the expression 
of glial fibrillary acidic protein (GFAP). The effects in response to loss of S100β are mediated 
by a reduced activation of the RhoA-ROCK and PI3K/Akt cascades (Brozzi et al., 2009). During 
stressful conditions, or in the event of acute or chronic insult to the brain, healthy astrocytes 
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undergo a process to form a scar in order to protect other healthy cells and prevent any infections 
form spreading. Astrocytes then release signaling molecules that cause microglia to release 
several signaling molecules resulting in a profound inflammatory response. This change from a 
normal healthy astrocyte to a scar forming one is slow and gradual. In the event of an acute 
injury, astrocytes become reactive, signal microglia to cause inflammation and release 
molecules and growth factors that are necessary to repair the damage, and then go back to their 
resting state. At a chronic level, astrocytes do not go back to resting state, and together with the 
microglia cause a proinflammatory response. This change in structure is often accompanied by 
a loss of several functions and a gain of some, some of which are helpful while others are 
detrimental. Thus, it is imperative to understand that at what point do these structural and 
functional changes start becoming detrimental. This may serve therapeutic purposes in reversing 
or ameliorating astrogliotic changes or promoting the necessary ones, and inhibiting the 
detrimental ones. Structural changes in astrogliosis involve changes in all types of cytoskeletal 
proteins including actin, tubulin as well as intermediate filaments. (Sofroniew, 2015). 
As discussed in the previous chapter, a disruption in astrocytic glutamate uptake is 
observed with loss of IGF-1 signaling. Since the function of a cell is intricately related to its 
structure, we question whether loss of IGF-1 signaling alters the structure of astrocytes via 
modulation of S100β. In our preliminary data from immunocytochemistry studies performed in 
cultured astrocytes treated with PPP, a visual change in the distribution of S100β and actin was 
observed. Based on the observations from the studies mentioned above and our preliminary data, 
we hypothesize that loss of IGF-1 signaling alters astrocyte migration and structure by 
dysregulating S100β. A schematic representation of our hypothesis can be found in Figure 3.1. 
To examine this, we pharmacologically inhibited IGFR in cultured astrocytes using PPP and 
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examined the distribution, expression and release of S100β. We further explored the canonical 
IGF1 signaling cascades, PI3K/Akt and RhoA-ROCK. 
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Figure 3.1. Schematic showing hypothesized regulation of astrocyte structure mediated by S100β 
mediated by IGF-1. S100β regulates stress fiber assembly and disassembly and astrocyte 
migration via PI3K stimulated RhoA-ROCK pathway and Akt phosphorylation respectively. 
IGF-1 stimulates PI3K mediated Akt phosphorylation in astrocytes. Therefore, we hypothesize 
that inhibition of IGFR will reduce the stimulation of PI3K and reduce astrocyte migration and 
disrupt astrocyte morphology mediated by S100β. 
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3.2. Materials and methods  
Animals 
All procedures were approved by and followed the guidelines of the Institutional Animal 
Care and Use Committee at the University of Mississippi. Wild-type Sprague Dawley female 
rats were purchased from Envigo with an estimated pregnancy date of embryonic day 16-17 
upon arrival to the animal facility. The dam was housed until birth when the pups were 
euthanized via rapid decapitation to extract cortical tissue. Tissues from all pups in the litter 
(both males and females) were pooled for in vitro cell culture. 
Materials 
Picropodophyllotoxin (catalog T9576) was purchased from Sigma-Aldrich 
Chemicals. Human S100B DuoSet ELISA kit was purchased from R&D systems (DY1820-
05). 2-APB (Cat. No. 1224), Ryanodine (Cat. No.1329) and Gap26 were ordered from Tocris 
(Cat. No. 1950). 
3.2.1. Astrocyte cultures 
Astrocytes were derived from the cortex and hippocampus of late-stage embryonic or 
early-stage post-natal Sprague Dawley rats, following a previously established protocol 
(McCarthy & De Vellis, 1980). The cortices and hippocampi of all male and female pups in 
the litters were combined and mixed throughout the culture process. Isolated tissue was 
enzymatically and mechanically digested using papain and trituration, respectively. After 
digestion, cells were resuspended in growth media. For rats, this media consisted of 
Neurobasal medium containing 10% fetal bovine serum, penicillin/streptomycin (10 
units/mL), and Lglutamine (29.2 μg/mL). 
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3.2.2. Immunocytochemistry 
Cultured astrocytes were grown onto coverslips for immunostaining to determine 
cellular composition. Cells were fixed using 4% paraformaldehyde in phosphate buffer for 15 
minutes at room temperature. After fixation, they were washed with cold phosphate buffered 
saline, permeabilized with 0.1% TritonX-100 for 15 minutes, and blocked in 1% bovine serum 
albumin, 22.52 mg/mL glycine in phosphate buffered saline with 0.1% Tween 20 for 30 
minutes. The cells were then incubated with polyclonal rabbit S100B (1:1000) 1% bovine serum 
albumin overnight at 4 °C. After three washes with phosphate buffered saline, IRDye 800CW 
Goat Anti-Rabbit IgG Secondary Antibody, DyLight 800 (1: 10,000 ThermoFisher Scientific) 
was applied to the coverslips for 1 hour at room temperature. Coverslips were washed in 
phosphate buffered saline three times and were subsequently mounted overnight in Prolong 
Gold Antifade with DAPI (4′,6-diamidino-2-phenylindole) mounting media (Molecular Probes) 
Imaging was then carried out using an inverted Nikon T2 microscope. 
3.2.3. S100β ELISA 
Astrocyte cultures were treated with increasing concentrations of PPP ranging from 0 to 
5 µM. Twenty-four hours after the treatment, the supernatant was used for analysis of S100β 
levels using the ELISA kit purchased from R&D. Briefly, a 96-well plate was coated with the 
antibody solution overnight at room temperature. Each well was then washed and blocked before 
performing the assay. 50 µL of the sample was diluted in 50 microliters of the diluent supplied. 
All the subsequent steps were performed as described in the manufacturer’s protocol. Briefly, the 
sample was diluted with the diluent supplied by the manufacturer, incubated with the antibody 
for 2 hours, washed, incubated with the secondary conjugated antibody, washed, subsequently 
followed by the addition of substrate.  
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3.2.4. Western Blotting 
Cells were lysed in 1X RIPA buffer with protease and phosphatase inhibitors. Protein 
was quantified using a DC protein assay kit (Biorad, Catalog number-5000112) following 
manufacturer’s protocol. Samples were run on a 10% Bis-tris gel with MOPS buffer for 1.5 
hours, transferred at 30 volts for 1 hour using the XCell SureLock transfer system. Western 
blotting was performed using the following primary antibodies: Mouse polyclonal anti-RhoA 
antibody- (1:1000), Rabbit polyclonal anti-ROCK1 antibody (1:500), mouse polyclonal anti-
Akt (1:000) and rabbit polyclonal anti-pAkt (1:1000). Mouse and rabbit polyclonal anti-
GAPDH antibodies were used as the loading controls. Secondary antibodies used were IRDye 
680RD Goat Anti-Rabbit and Goat anti-mouse. Imaging was done using a LICOR/Odyssey 
imaging station. 
Statistical analysis 
Experiments were designed considering statistical power and sample size estimation. We 
have set β at 0.8 and α at 0.05. Based on pilot studies in our laboratory, we are able to estimate 
the baseline variability and determine most of the in vitro studies require sample sizes of 5-
6. Analysis was performed using SigmaPlot v13 software. A t-test or one-way ANOVA with 
subsequent Dunnett’s tests were used to compare difference between groups. 
3.3. Results 
3.3.1. Pharmacological inhibition of IGFR causes astrocytes to cluster together 
In our preliminary immunocytochemistry experiments, visual changes in the distribution 
of cells stained for actin and S100β was observed (Figures 3.2-3.5). We assessed these changes 
in distribution by quantifying the area unoccupied by the cells using Nikon image analysis 
software. On analyzing the data, a statistically significant difference between the control and 
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PPP groups was not observed (p=0.06)  
 
 
Figure 3.2. Preliminary data depicting changes in cellular distribution in response to IGFR 
inhibition in astrocytes. Primary cultured astrocytes are treated with 5 µM of PPP for 24 hours, 
and then fixed, blocked and costained with the Alexa 546 conjugated phalloidin antibody to stain 
cytoskeletal protein actin and astrocyte marker and calcium binding protein S100β. A) 
Representative image of cultured astrocytes grown on cover slips and treated with DMSO for 24 
hours (Control group) and costained for Actin and S100β B) Representative image of cultured 
astrocytes grown on cover slips and treated with 5 µM PPP for 24 hours and costained for Actin 
and S100 β.   
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Figure 3.3. Preliminary data depicting changes in cellular distribution in response to IGFR 
inhibition in astrocytes. Primary cultured astrocytes are treated with 5 µM of PPP for 24 hours, 
and then fixed, blocked and stained with the Alexa 546 conjugated phalloidin antibody to stain 
cytoskeletal protein actin A) Representative image of cultured astrocytes grown on cover slips and 
treated with DMSO for 24 hours (Control group) and stained for Actin B) Representative image 
of cultured astrocytes grown on cover slips and treated with 5 µM PPP for 24 hours and stained 
for Actin.   
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Figure 3.4. Preliminary data depicting changes in cellular distribution in response to IGFR 
inhibition in astrocytes. Primary cultured astrocytes are treated with 5 µM of PPP for 24 hours, 
and then fixed, blocked and stained with Rabbit polyclonal antibody against S100β and then 
stained with an Anti-rabbit secondary Alexa 488 stain to stain astrocyte marker protein S100β 
(Top) Representative image of cultured astrocytes grown on cover slips and treated with DMSO 
for 24 hours (Control group) and stained for S100β, (Bottom) Representative image of cultured 
astrocytes grown on cover slips and treated with 5 µM PPP for 24 hours and stained for S100β. 
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Figure 3.5. Quantification of changes in the cellular distribution in response to inhibition of IGFR. 
Changes in the cellular distribution in response to inhibition of IGFR were not found to be 
significantly different from the astrocytes in the control group. Primary cultured astrocytes are 
treated with 5 µM of PPP for 24 hours, and then fixed, blocked and stained with Rabbit polyclonal 
antibody against S100β and then stained with an Anti-rabbit secondary Alexa 488 stain to stain 
astrocyte marker protein S100β. Images obtained were analyzed for changes in cellular 
distribution by quantification of space between cell clusters shown in the previous Figures 3.2-
3.4. Several Regions of Interest (ROIs) were drawn per field, and the total area of ROIs was 
calculated and quantified. (The data are expressed as mean±SE of 10-15 cover slips, per group, 
t-test) 
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3.3.2. Pharmacological inhibition of IGFR does not induce concentration-dependent 
localization of S100β. 
In addition to the clustering of cells, localization of S100β around the nucleus was also 
observed during immunocytochemistry experiments. To assess whether the visual differences 
in S100β localization (Figure 3.4) were statistically significant and dependent on the 
concentration of PPP, we examined the effects of a full concentration curve with PPP. Cultured 
astrocytes grown on coverslips were treated with increasing concentrations of PPP from 0 µM 
to 5 µM for twenty-four hours, fixed, stained and imaged. Quantification was performed using 
both manual scoring and software-based scoring methods. In the manual method, images were 
scored on a scale of 1-3 with 1 showing changes in localization to the lowest degree, while 3 
being the highest. In the software-based analysis, Pearson’s correlation coefficient between the 
stains used for staining the nucleus and S100β was calculated. Based on the images acquired, 
we had expected greater localization changes with higher concentrations of PPP (Figure 3.6 A). 
However, on analyzing the data with manual and automated methods (Figure 3.6 B and C), no 
significant differences between the treatment groups were observed. Thus, no significant 
changes in S100β localization in response to loss of IGF1 signaling were observed. 
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Figure 3.6. S100β localization in response to inhibition of IGFR with varying concentrations 
of PPP for 24 hours. Control astrocytes are treated with DMSO. Manual scoring analysis and 
software-based analysis shows that data is not significantly different between the control and 
PPP treatments. A) Representative images showing cultured astrocytes stained for S100β after a 24-
hour treatment with varying concentrations of PPP B) Manual scoring of S100B localization. 
C) Pearson’s correlation coefficient of S100B localization (Data are represented mean±SE of 
10-11 fields (total of 3-4 coverslips) per group, One-way ANOVA) 
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3.3.3. Pharmacological inhibition of IGFR does not induce time-dependent localization 
of S100β. 
In a separate set of experiments, cultured astrocytes grown on coverslips were treated 
with 5 µM for varying times ranging from fifteen minutes to twenty-four hours. To assess 
whether there is any effect of duration of PPP treatment on the localization of S100β, 5 µM PPP 
was applied to cultured astrocytes and immunocytochemistry was performed at time points 0, 
15, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours and 24 hours. Based on the images acquired, 
we had anticipated changes in the localization of S100β to be occurring as early as 4 hours 
(Figure 3.7 A). However, on using the Pearson’s correlation coefficient and manual scoring to 
analyze the images, no significant change was observed (Figure 3.7 B and C) indicating that 
inhibition of IGFR does not induce time-dependent localization. 
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Figure 3.7. S100β localization in response to inhibition of IGFR after varying durations of 5 
µM PPP. Manual scoring analysis as well as automated software-based analysis of the data 
shows data is not significantly different between the control and PPP treatments. A) 
Representative images showing cultured astrocytes stained for S100β after treatment with 5 µM PPP 
for varying durations ranging from 15 minutes to 24 hours. Control astrocytes were assessed at 
0 minutes. B) Manual scoring of S100B localization. C) Pearson’s correlation coefficient of 
S100B localization (Data are represented mean±SE of 10-11 fields (total of 3-4 coverslips) per 
group, One-way ANOVA) 
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3.3.4. Blocking calcium signaling has no effect on localization of S100β 
Astrocytes cultured on coverslips were treated with 5 µM PPP with and without calcium 
release/receptor blockers like Gap26, 2-AP, and Ryanodine were applied. Localization of 
S100β was assessed after three hours by immunocytochemistry. No significant difference was 
observed between our control, PPP and Gap26 (gap junction blocker), Ryanodine (Ryanodine 
receptor blocker) and calcium free media treated cells. However, contrary to our expectation, 
cells treated with 2-APB showed a significantly higher Pearson’s correlation value (Figure 3.8). 
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Figure 3.8. Quantification of S100β localization in response to calcium blockade and inhibition 
of IGFR. Cultured astrocytes grown on coverslips were treated with 5 µM PPP and calcium 
blockers like Gap26, RyR, 2-APB and calcium free media. Positive control astrocytes were 
treated only with PPP and no calcium inhibitor, while negative control group consisted of cells 
treated with DMSO. Blocking calcium signaling in cultured astrocytes treated with PPP did not 
have any significant effect on localization of S100β. Cells treated with 2-APB showed a higher 
degree of Pearson’s correlation, while PPP treated cells did not. (Data are represented a mean±SE 
of 10-11 fields (total of 3-4 coverslips) One-way ANOVA, Post-hoc Dunnet’s test. p<0.05) The 
*indicates a significant difference as compared with controls, # indicates a significant difference 
in comparison to PPP) 
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3.3.5. Inhibition of IGFR does not cause any changes in the levels of S100β protein. 
In order to examine the effect of IGFR inhibition of S100β protein levels, 5 µM PPP was 
applied to astrocyte cultures for 24 hours, and levels of S100β were assessed. No change in the 
levels of S100β was found in the cell lysates (Figure 3.9 A). Additionally, release of S100β in 
response to application of 5 µM PPP was also measured but was not found to be significant 
(Figure 3.9 B). Thus, inhibiting IGFR in cultured astrocytes does not alter the expression or 




Figure 3.9. Quantification of S100β levels in response to inhibition of IGFR. Cultured astrocytes 
were treated with 5 µM PPP for 24 hours, and extracellular release and total S100β protein 
expression was measured later. Control astrocytes were treated with DMSO. Inhibition of IGFR 
in cultured astrocytes did not have any significant effect on the total expression or release of 
S100β protein. A) Protein expression of S100β in cultured astrocytes after IGFR inhibition with 
PPP (Data are represented a mean±SE of 5-6 replicates, t-test). B) Levels of S100β protein release 
into the extracellular media after 24 hours of IGFR inhibition by PPP as measured by an ELISA 




3.3.6. Pharmacological inhibition of IGFR does not cause changes in astrocyte structure via 
the Rho-ROCK cascade. 
To assess the effect of loss of IGF-1 signaling on astrocyte structure, we examined the 
expression of signaling proteins involved in the Rho-ROCK and P13K-Akt signaling cascades 
with a short-term and long-term inhibition of IGFR. No change was observed in the expression 
of RhoA and ROCK 1 levels at 4 hours or 24 hours, indicating the changes in the structure were 
independent of the Rho-ROCK signaling cascade. Additionally, no change in the 
phosphorylation of Akt was observed at 4 or 24 hours. Thus, these data indicate that loss of IGF- 




Figure 3.10. PI3K signaling cascade in response to short-term inhibition of IGFR. Cultured 
astrocytes were treated with 5 µM PPP for 4 hours, and protein expression of downstream 
signaling proteins in the PI3K cascade was measured later. Control astrocytes were treated with 
DMSO. Inhibition of IGFR in cultured astrocytes did not have any significant effect on PI3K 
signaling cascade. A) Relative protein expression of RhoA in cultured astrocytes after IGFR 
inhibition with 5 µM PPP or DMSO B) Relative protein expression of ROCK1 in cultured 
astrocytes after IGFR inhibition with 5 µM PPP or DMSO C) Phosphorylation of Akt in cultured 
astrocytes after IGFR inhibition with 5 µM PPP or DMSO (Data are represented a mean±SE of 





Figure 3.11. PI3K signaling cascade in response to long-term inhibition of IGFR. Cultured 
astrocytes were treated with 5 µM PPP for 24 hours, and protein expression of downstream 
signaling proteins in the PI3K cascade was measured later. Control astrocytes were treated with 
DMSO. Inhibition of IGFR in cultured astrocytes did not have any significant effect on PI3K 
signaling cascade. A) Relative protein expression of RhoA in cultured astrocytes after IGFR 
inhibition with 5 µM PPP or DMSO B) Relative protein expression of ROCK1 in cultured 
astrocytes after IGFR inhibition with 5 µM PPP or DMSO C) Phosphorylation of Akt in cultured 
astrocytes after IGFR inhibition with 5 µM PPP or DMSO (Data are represented a mean±SE of 




Astrocytes execute numerous functions in the healthy brain including glutamate uptake 
and conversion to glutamine, release of gliotransmitters and neurotrophic factors (Sofroniew 
& Vinters, 2010). All of these functions require astrocytes to be a part of tripartite synapses 
and modulate synaptic plasticity. These functions are affected when astrocytes respond to and 
contribute to pathologies in the CNS by becoming reactive. This process is known as 
astrogliosis, where they undergo morphological changes and contribute to inflammatory and 
neurodegenerative pathways in the brain (Sofroniew, 2015). In addition to these functional 
changes, astrocytes also undergo structural changes during astrogliotic scar formation. One of 
these changes include remodeling of the cytoskeleton via rearrangement of actin filaments 
(Schiweck et al., 2018). 
In our preliminary data, we observed abnormalities in the actin cytoskeleton when IGFR 
was inhibited. On quantification of the surface area not occupied by these cells, we observed 
that inhibition of IGFR causes astrocytes to cluster together (p=0.06). In addition to the changes 
in actin, we also saw a visual change in the localization of S100β in these cells. One study 
showed that a decrease in S100β expression increases the expression of GFAP, a classic marker 
of astrogliosis (Brozzi et al., 2009). As discussed previously, loss of IGF-1 is associated with 
increase in GFAP and astrogliosis. In order to examine if the loss of IGF1 signaling alters 
astrocyte structure via S100β, we first sought to quantify the changes in localization of S100β. 
We therefore quantified the localization of S100β at multiple time points ranging from 0-24 
hours and concentrations of PPP ranging from 0 to 5 µM. In the past most studies relied on 
visual assessment of immunocytochemistry pictures. However, that is not a rigorous way of 
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analyzing data, and recent studies have applied the method of manual scoring by multiple scorers 
blinded to these experiments. Although, manual scoring does account for some reliability in the 
data obtained, the most ethical, accurate and reliable way to analyze images is to make use of 
softwares like ImajeJ, Cell Profiler, and IHC Profiler. Here we utilized both manual scoring and 
NIS-Elements software by Nikon to analyze our distribution data. With manual scoring, images 
were scored from 1-3 based on the degree of localization of S100β. We also measured the 
Pearson’s correlation coefficient as a measure of degree of colocalization of S100β with the 
nucleus. This was measured in 12 different ROIs in a single field. Based on visual assessments, 
we had expected a higher value of correlation in the cells treated higher concentrations of PPP 
or longer durations. However, we did not observe a significant correlation between localization 
of S100β and concentration or duration of treatments. Since S100β is a calcium sensing protein, 
our next step was to examine if blockade of calcium signaling causes any changes in S100β 
localization. With calcium blockade, we observed no changes between our PPP and DMSO 
controls. Also, 2-APB treated cells had a higher Pearson’s correlation value than PPP treated 
cells. While this may be an effect of the drug itself, we still cannot exclude the fact that DMSO 
and PPP treatments were not different. A possible explanation would be a 3-hour treatment does 
not do much to contribute to the changes observed at 24 hours. 
A reduction in S100β expression leads to changes in actin cytoskeleton via decreased 
activity of RhoA and ROCK1. Additionally, phosphorylation of downstream effector of PI3K, 
Akt is reduced (Brozzi et al., 2009). As described previously in chapter 1, IGF-1 signaling 
stimulates the PI3K/Akt pathway in astrocytes. Therefore, we were curious as to how loss of 
IGF-1 signaling would influence these pathways. We measured total protein levels as well as 
the release of S100β. Both the total expression did not change and release levels did not change. 
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We assessed the protein levels of RhoA and ROCK1 both at 4 hours and 24 hours to examine 
if there were any alterations. We also measured the phosphorylation of Akt at 4 hours and 24 
hours. However, we did not observe any changes in this pathway, thus confirming the fact loss 
of IGF1 signaling in astrocytes does not regulate their structure via the Rho-ROCK cascade. 
A major limitation of this study is the method of analysis of the images. Even though 
Pearson’s correlation constant has been in use for analysis of colocalization, it may not 
necessarily be the most appropriate way to do so. This is especially applicable when cells are 
tightly clustered together in multiple layers as in this study, as the software would then measure 
intensities of the dyes in all those layers. A possible solution could be growing the cells on these 
coverslips at a lower confluence so that grow in a single layer. Additionally, astrocytes can be 
transfected to stably express a fluorescently tagged version of S100β and then treated with PPP 
as described in the experiments performed here. To examine the specific changes occurring to 
S100β and actin distribution, a time-lapse microscopy can be performed with these astrocytes. 
Furthermore, to analyze the data obtained from time-lapse microscopy, cell profiler could be 
utilized. Additionally, we can then utilize the fractional proliferation method to assess the 
changes in cell quiescence over time (as described in Tyson et al., 2012). 
Conclusion 
Overall, our data indicate that loss of IGF-1 does not cause rearrangement of actin 
cytoskeleton via S100β signaling of Rho-ROCK cascade. A different signaling cascade may be 
involved in mediating the actin cytoskeleton remodeling. Future directions should examine the 
relationship between loss of IGF-1, modulation of extracellular matrix in these cells by 
substances and signaling molecules like the NCAM, SynCAM, etc. expressed by astrocytes. 
Additionally, changes in the localizaµtion of S100β, or formation of higher order structures that 
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may take part in aggregation of proteins containing beta sheets should be examined. A possible 
involvement of RAGE-NFkβ pathway in neuroinflammation in response to IGFR inhibition 
may be present and should be explored further. Above all, better ways of analyzing data from 
the images obtained from these experiments would help shed light on the effects of IGFR 









IGF-1 regulates cognition in rodents as well as humans. Human and animal studies 
have reported contradictory data regarding the relationship of IGF-1 and age-associated or 
neurodegeneration-associated cognitive decline. Owing to the pleiotropic effects of IGF-1 in 
the brain, teasing apart the response or contribution of the many cell types in the brain to 
IGF-1 decline has been challenging. Most of the work to date has focused on examining the 
effect of circulating IGF1 signaling on cognition with a focus on neurons. However, there is a 
need to study IGF-1signaling in the context of other brain cells expressing IGF-1 and IGFR. 
Here, we examined the role of IGF-1 signaling in regulating cognition through 
astrocytic IGFR. To do this, we utilized the Cre-Lox system to induce astrocytic IGFR 
deficiency in vivo and created novel mouse models with astrocyte-specific IGFR deficiency 
(aIGFR-KO). We then assessed a set of cognitive behavioral phenotypes in these mice. 
Reduction in IGFR signaling did not impair cognition in males or females. Interestingly, 
changes in the levels of some excitatory amino acids, as well as altered expression of some 
astrocytic and neuronal genes associated with the glutamate-glutamine cycling were observed 
with astrocyte IGFR reduction in males. Interestingly, some markers associated with neuronal 
stress were also elevated. Together, these data suggest that impaired IGF-1 signaling may 
dysregulate certain astrocyte functions that may contribute to cognitive decline associated in 
aging or neurodegeneration. 
4.2. Introduction 
4.2.1. IGF-1 and Cognition 
IGF-1 is an important growth factor in the body playing a crucial role in overall 
development of an organism (Yamamoto et al., 1991). About 70 % of IGF-1 in the body is 
derived from the liver. As a result, a number of early studies examined the effects of liver 
IGF-1 deficiency on development, growth and cognition. Reportedly, liver-derived IGF-1 can 
be associated with cognition in both animal models and humans (Aleman et al., 1999; 
Okereke, et al., 2006; Okereke et al., 2007; Trejo et al., 2008). 
The IGF-1 field has reported contradictory results and opinions regarding the role 
played by IGF-1 in aging and cognition. One of the models for studying IGF-1 and cognition 
is the liver- IGF-1 deficient (LID) mouse. LID mice have been studied extensively in the 
context of several disorders, and their behavior is well characterized to show learning and 
memory deficits in a hippocampal-dependent spatial learning and memory task, and impaired 
long-term potentiation (Trejo et al., 2007). These mice also exhibit anxiety-like and 
depression-like phenotypes and can be used to study other mood disorders (Gubbi et al., 2018; 
Mitschelen et al., 2011). Some studies have shown that reducing IGF-1 signaling is beneficial 
in preventing age-associated pathologies and have beneficial effects on lifespan in both 
rodents and humans (Sonntag et al., 2005). Additionally, supplementing aged rodents as well 
as humans with growth hormone or IGF-1 reverses their cognitive decline (Deijen et al., 1998; 
Pardo et al., 2016). On the other hand, some studies have reported a negative correlation or no 
correlation between IGF-1 levels and cognition or lifespan in humans as well as animal models 
(Kinney et al., 2001; Perice et al., 2016; Tumati, et al., 2016). In addition to aging, the role of 
IGF-1 in the associated cognitive decline associated with several other neurological disorders 
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like Alzheimer’s disease, Parkinson’s disease, Stroke, and TBI has been controversial (Gubbi 
et al., 2018). 
Due to the pleiotropic effects of IGF-1, teasing apart the roles, mechanisms and 
pathways it regulates in a diseased brain has been a challenge. This challenge has been further 
compounded by the fact that IGF-1 may have different effects on different brain cells, and 
regulate different mechanisms under different conditions. As a result, there is a need to 
explore models that facilitate the examination of IGF-1 signaling in one cell type under a 
given set of circumstances. Preliminary evidence in our lab suggests that neuron-specific 
IGFR-KO mice show deficits in spatial learning and memory. However, the neuron-centric 
approach of most studies fail to recognize the importance of other brain cell types like 
astrocytes that also express IGFR. Since astrocytes are the most abundant cell type in the brain 
expressing IGFR, it is important to study the contribution of IGF-1 signaling in astrocytes in 
response to the changing microenvironment of the aging brain. 
4.2.2. Astrocytes and IGF-1 
Astrocytes perform a number of crucial functions ranging from uptake of glutamate, 
removal of toxic substances, and secreting gliotransmitters and trophic substances, to working 
in conjunction with the microglia to regulate immune responses in the brain (Parpura & 
Haydon, 2009). Astrocytes produce IGF-1 which protects neurons from oxidative stress in 
vitro (Genis et al., 2014). Additionally, IGF-1 is shown to reduce behavioral deficits in mice 
due to injury in vivo (Madathil et al., 2013). We recently reported that astrocyte glutamate 
uptake is reduced with a loss of IGF-1 signaling (Prabhu et al. 2019). Additionally, with the 
help of the glutamate-glutamine cycle, astrocytes provide metabolic support to neurons. They 
are also involved in memory consolidation (Gibbs et al., 2008). Another recent study showed 
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that astrocyte specific IGFR-KO mice exhibit impaired working memory, mitochondrial 
metabolism and amyloid beta uptake (Logan et al., 2018). However, several questions have 
not been addressed by this study due to its less rigorous design of experiments and analysis. 
Based on the above findings, we hypothesized that loss of astrocytic IGFR signaling 
would negatively affect cognition in mice. To do this, we generated our novel inducible 
astrocytic specific IGFR mice models referred here as aIGFR-KO mice, using the Cre-Lox 
system. We subjected our novel mice to a series of behavioral assays carried out in a specific 
sequence as shown in Figure 4.1. Behavioral tests assessed were: Anxiety-like behavior using 
the elevated plus maze, depression-like behavior using tail suspension test, spatial learning 
and memory using the Barnes maze and Radial Arm water maze, motor learning and co- 
ordination using the Rotarod test, and grip strength using the grip strength apparatus. 
Mechanistically, we measured the level of certain amino acids, and certain markers associated 
with stress in the brains of aIGFR-KO animals. Additionally, we also assessed the expression 
of some genetic machinery involved in glutamate-glutamine cycle. Overall this study helped 
us uncover the role of astrocytic IGFR in regulating cognition under conditions of decreased 
IGF-1 signaling as is observed in aging and neurodegeneration. 
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Figure 4.1. Schematic diagram showing the generation of astrocyte-specific IGFR KO mice 
(aIGFR-KO) and order of testing of behavioral assays. IGFR flox mice are crossed several types 
with iGFAP-Cre mice to generate igfrf/f-iGFAP-Cre mice. The correct genotype is verified using 
genotyping PCR. IGFR deficiency is induced after puberty at around 3-4 months via i.p. 
injections of Tamoxifen and behavioral testing is carried out in the order shown above. 
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4.3. Materials and methods  
Animals 
All the procedures were approved by and followed the guidelines of the Institutional 
Animal Care and Use Committee (IACUC) at the University of Mississippi. Male and female 
mice were purchased from Jackson Laboratories (strain 012251) and bred inhouse. For 
breeding, two female igfrf/f mice were crossed with one male GFAP-Cre/ERT mouse in a 
cage. The genotypes of all pups were confirmed using the PCR protocols defined by the 
Jackson laboratories. Male pups with the GFAPCre/ERT+ and igfrf/+ genotype were bred 
with igfrf/f females for a second generation. The subsequent generations were bred from 
resulting GFAP-Cre/ERT+ and igfrf/f male mice and igfrf/f females. At three months of age, 
following genotype verification, mice were assigned to treatment for an injection with corn oil 
or tamoxifen, which induces Cre recombinase expression. Assignment to treatment group was 
performed using block randomization, to ensure equal n per treatment group. For this, the total 
animal number for each sex was divided in two, and cages were assigned to the treatment 
group to add up to the appropriate number of animals while allowing for all animals in the 
cage to receive the same injection. An individual not performing the injections was responsible 
for treatment assignment. Tamoxifen was diluted in corn oil, heated to 50 degrees celsius to 
solubilize, cooled, and administered via intraperitoneal injection in a 75mg/kg dose. Corn oil 
not only increases solubility of tamoxifen, but it also decreases inflammation at the site of 
intraperitoneal injection. Dosing was repeated for 5 consecutive days. No distress was noted 
during or following injections. Two months later, mice were euthanized via rapid decapitation 
and brains were extracted for analysis. In this study, 49 GFAP-Cre/ERT+ and igfrf/f+ mice 
were included (22 females, 27 males). The average weights of the mice were 27+/-2.0 g for 
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male controls, 28.4 +/1.4 for male knockouts, 20.8+/-0.00 g for female controls, and 20.8+/-
1.74 g for female knock-outs. Knock-out was validated with qPCR of IGFR exon 3, the exon 
targeted during recombination. One female mouse was excluded from the data set as she 
exhibited an increase in IGFR expression rather than a decrease following tamoxifen injection. 
All animals were housed with enriched bedding, and provided standard rodent chow (5053 
Pico Lab, Purina Mills, Richmond, IN) and water ad libitum. Mice were housed in 
SuperMouse750 (12x5.5 inch) ventilated cages. Mice were genotyped for the presence of the 
igfrf/f exon 3 loxp sites and the iGFAP-Cre transgene. For this, 2-3 millimeter of tails were 
clipped and RNA was extracted using Sigma REDExtract-N-AMP Tissue PCR Kit (XNAT) 
following manufacturer recommendations. The following primers were used for PCR 
amplification, following the recommendations of Jackson laboratories for thermal cycling for 
each primer set: IGFR forward 5’ CTT CCC AGC TTG CTA CTC TAG G 3’, IGFR reverse 
5’ CAG GCT TGC AAT GAG ACA TGG G 3’, iGFAP forward 5’ GCC AGT CTA GCC 
CAC TCC TT 3’, GFAP reverse 5’ TCC CTG AAC ATG TCC ATC AG 3’. The resulting 
PCR product was run on a 1.5% agarose gel with Greenglo (Denville CA3600) for one hour at 
100V. The gel was imaged and each lane was compared to positive and negative controls on 
the gel. 
Assessment of Spatial Learning and Memory 
Spatial Learning and Memory was assessed using Radial Arm Water maze and Barnes maze. 
The maze was purchased from San Diego Instruments (24 x 8 cm arms with a 18cm center, 
with the hidden platform 6 x 8cm). The maze was filled halfway with water (one cm above the 
hidden platform placed in one of the arms), one day prior to carrying out the trials (this allows 
the water to equilibrate to room temperature). The water was colored white using white food 
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color. Each arm of the maze had a unique visual cue pasted onto the wall. On the day of the 
trials, before the start of acquisition, animals were acclimated to the platform for 30 seconds. 
Throughout the course of the study, each animal received 8 trials of acquisition for three days, 
1 probe trial on day 10 and 8 trials of reversal on day 11. During the acquisition and probe 
phases, the platform was located in arm 3. This platform was then moved to arm 8 during the 
reversal phase. The animals were placed in different cages (supplied with food and water) on 
heating pads. The animals were returned to their home cages after each day’s set of trials were 
done. Each time, the animals that did not find the platform during a trial was directed toward 
the platform. Path length, latency, velocity and number of errors were quantified using the 
Noldus Ethovision Software. 
Assessment of Anxiety-like behavior 
Anxiety-like behavior was assessed using the elevated plus maze (as described in 
(Walf et al. 2007)). The maze was purchased from Columbus Instruments (consisted of two 
open and two enclosed arms (61×5 cm) connected to a central area (5×5 cm)). At the start of 
each trial, the mouse was placed in the center of the maze facing an open arm. Each mouse 
was given a trial of 5 minutes, during which the amount of time spent by the mouse in closed 
arms was quantified using the Noldus Ethovision Software. 
Assessment of Depression-like behavior 
Depression-like behavior was assessed using the tail-suspension task (as described in 
(Can et al. 2012)). Mice were suspended from their tails and videotaped for approximately 5 
min. The tails were wrapped in adhesive tape at approximately three-quarters the distance 
from the base to suspend the mice. The number of attempts to reach the tail by the bending 
the body and crawling up the tail were quantified. Also, the time to complete immobility was 
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also recorded. 
Assessment of Muscular Strength 
Muscle strength was assessed using the grip strength apparatus. Mice were made to 
hold onto the grid-like structure of the instruments, and a gentle pull was applied at the base 
of the tail. The maximum amount of force displayed on the sensor was recorded before the 
mouse let go. Each mouse was given a set of three trials. The average of all three readings 
was quantified. 
Assessment of Motor coordination 
Motor coordination was assessed using the Rotarod apparatus. Each animal received 1 
session per day. Each daily session consisted of 5 consecutive runs. The animals were 
acclimated to the room for one hour. Prior to Run 1 on day 1, the animals were acclimated to 
the instrument for three minutes. Animals were tested for three consecutive days. 
Assessment of Urea and Amino acids in the brain 
Briefly, tissue from one half of brain was flash frozen with liquid nitrogen, weighed, 
processed using ice cold 10% SSA (5-Sulfosalicylic acid) 3X volume to powdered tissue and 
homogenized. It was then centrifuged at 3000g for 15 minutes. The supernatant was decanted 
and sent to Vanderbilt Hormone Assay and Analytical Services Core for amino acid analysis. 
Serum Urea ELISA  
Serum samples were collected after euthanizing animals, and the amount of urea was 
quantified in these serum sample using an ELISA kit purchased from Abcam (ab83362). The 
ELISA was performed using mouse serum samples as per the manufacturer’s protocol. 
Briefly, serum samples with dilution were incubated with the reaction mix containing assay 
buffers, reaction enzymes and substrate, at 37 degrees Celsius for 1 hour and then absorbance 
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was measured at 570 nm.  
Gene expression 
Tissues from the animals were harvested to examine changes in mRNA expression. 
Roughly 10 mg of cortical tissue was used for RNA extraction. Total RNA was isolated using 
the RNAeasy mini kit (Qiagen). cDNA was made using High-Capacity RNA-to-cDNA kit 
(Applied Biosystems). RT-PCR was performed using TaqMan Universal PCR Master mix (Life 
Technologies) and TaqMan validated primers on the CFX Connect Real time PCR detection 
system (Bio-Rad). Results were normalized to HPRT and GAPDH and YWHAZ. The 
experimenter was unaware of treatment group during experimentation, and the assignment code 
was cracked following double delta CT analysis. 
Immunohistochemistry 
The brains from mice were fixed using 4% paraformaldehyde (in phosphate buffer), 
immersed in 30% sucrose (in phosphate buffer) and then embedded in Optimal cutting 
Temperature (OCT) compound to be frozen. 35 µm sections were then generated using a 
cryostat and immunohistochemistry was performed as per vendor’s protocol. Every fourth 
section was used for staining. Briefly, the slices were washed 2 times with TBS plus 0.025% 
Triton X-100 with gentle agitation. Antigen retrieval was performed in Citrate buffer at 95 
degrees Celsius for 30 minutes. The slices were then cooled down for 20 minutes, washed, 
blocked using 10% Normal serum and 1%BSA for 2 hours. Primary antibody was added in 
1% TBS overnight at a dilution of (1:100). Secondary antibody was added at a dilution of 
(1:1000) for 1hr. The slices were mounted using Prolong anti-fade DAPI mounting medium 




Tissue was lysed and sonicated in 200 μL of RIPA buffer. Protein was quantified using 
a DC protein assay kit (Biorad, Catalog number-5000112) following manufacturer’s protocol. 
Samples were loaded at random by a blinded experimenter, run on a 10% Bis-tris gel with 1X 
MOPS buffer, transferred at 30 volts for one hour using the XCell SureLock transfer system. 
Western blotting was performed using the following primary antibodies: Rabbit polyclonal 
Anti-GFAP Antibody (1:1000), rabbit anti-Caspase-3 Antibody (1:1000), and mouse anti-
Caspase-9 Antibody (1:1000). GAPDH was used as the loading control. Secondary antibodies 
used were IRDye 680RD Goat anti-Rabbit and Goat anti-mouse antibodies. Imaging was done 
using a LICOR/Odyssey imaging station. 
Glutamine Synthetase Activity Assay 
Glutamine synthetase activity assay kit was performed from Cohesion Biosciences 
(CAK1021), and the assay was performed as per the manufacturer’s protocol. Briefly, 0.1 mg 
hippocampal tissue was lysed in 1 mL of assay lysis buffer and centrifuged at 8000g at 4º C for 
10 minutes, and the supernatant was used for the next steps. Supernatant was treated with 
Reaction buffers in the specified sequence and substrate was added, followed by 30-minute 
incubation at 37 degrees Celsius. Absorbance was measured at 540 nm.  
4.4. Results 
Astrocytic IGFR was knocked down in mice after puberty utilizing the Cre-LoxP 
system to induce IGFR deficiency in astrocytes using tamoxifen. Knockdown was verified 
using qPCR, and 60 % deficiency in IGFR (exon 3) was observed in these animals. 
Behavioral assays were performed 2-3 months after tamoxifen administration. 
  
88
Astrocytic-IGFR Deficiency and animal behavior 
4.4.1. Astrocytic IGFR deficiency in mice does not impair general locomotion 
General locomotion was assessed in astrocyte-specific knockout (aIGFR-KO) mice 
using the open field test. Specifically, distance moved and velocity were measured. No 
significant differences in distance or velocity were observed between aIGFR KO mice and 
controls in male or female cohorts (Figure 4.2 A-D), indicating that astrocytic IGFR 
deficiency does not impair locomotion in mice. 
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Figure 4.2. Assessment of general locomotion in mice after inducing aIGFR deficiency. 
Astrocytic IGFR deficiency does not alter general locomotion in mice. A) Total distance 
covered during exploration by male control and aIGFR mice during 10 minutes of trial using 
the open field apparatus B) Mean velocity exhibited by control and knockout male mice in the 
open field apparatus (The data is represented as mean±SE of 15 animals, t-test). C) Total 
distance covered during exploration by female control and aIGFR mice during 10 minutes of 
trial using the open field apparatus D) Mean velocity exhibited by female control and knockout 
mice in the open field apparatus (The data is represented as mean±SE of 20 animals, t-test). 
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4.4.2. Astrocytic IGFR deficiency in mice does not alter grip strength 
To examine whether astrocytic IGFR deficiency alters grip strength in mice, maximal 
force exhibited by the animals when made to hold the grid on the apparatus was recorded. No 
significant differences in grip strength was recorded between the control and aIGFR-KO 
groups in male and female cohorts (Fig 4.3 A and B). These data indicate that astrocytic 
IGFR deficiency does not alter muscle strength in mice. 
91
 
Figure 4.3. Assessment of grip strength in mice after inducing aIGFR deficiency. Astrocytic 
IGFR deficiency does not alter muscle strength or grip strength in mice. Maximum force 
achieved by the mouse to hold the grid of the grip strength meter was recorded during 3 trials 
and the data was averaged. A) Averaged maximum force exhibited by the control and aIGFR 
male mice during the test (The data is represented as mean±SE of 15 animals, t-test). B) 
Averaged maximum force exhibited by the control and aIGFR female mice during the test (The 
data is represented as mean±SE of 20 animals, t-test).   
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4.4.3. Astrocytic IGFR deficiency does not alter motor learning and coordination. 
To assess whether astrocytic IGFR plays a role in regulating motor learning and 
activity, rotarod test was utilized. The test was performed over a three-day period and latency 
to fall off the rod was recorded as a measure of motor coordination. No significant change in 
the latency to fall was observed between the groups over the three-day period. In male mice, 
their maximal performance was observed on Day 1, and did not improve much over the 
course of three days (Figure 4.4. A). Thus, there was no improvement in their performance 
over a three-day period, indicating the absence of motor learning. In females, a slightly better 
performance was seen in aIGFR-KO mice over days, but was it not significantly different 
from the control mice (Figure 4.4 B), indicating no role for astrocytic IGFR in regulation of 
motor learning and coordination. 
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Figure 4.4. Assessment of motor coordination in mice after inducing aIGFR deficiency. 
Astrocytic IGFR deficiency does not alter motor coordination in male or female mice. Animals 
were acclimated to the Rotarod apparatus and were trained to perform the task over a period of 3 
days. Latency to fall was recorded during each trial (25 rpm, 5 trials per day) for 3 days. A) 
Latency to fall exhibited by the control and aIGFR male mice during the test (The data is 
represented as mean±SE of 15 animals, two-way repeated measures ANOVA). B) Latency to fall 
exhibited by the control and aIGFR female mice during the test. (The data is represented as 
mean±SE of 20 animals, two-way repeated measures ANOVA). 
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4.4.4. Astrocytic IGFR deficiency does not lead to impairment in spatial learning and memory 
For assessing the effect of astrocytic IGFR deficiency on spatial learning and memory 
in mice, radial arm water maze was utilized. To assess learning, pathlength, velocity and 
number of errors were quantified over the three-day acquisition phase. In males, both aIGFR-
KO and control animals learned the task successfully over the course of three days. No 
significant difference in learning was observed between the groups as assessed by a two-way 
repeated measures ANOVA (Figure 4.5 A). Interestingly, it appeared that the male aIGFR-KO 
mice exhibited a higher velocity than the control mice, but on analyzing the data using two-
way repeated measures ANOVA, it was found to not be statistically significant. (Figure 4.5 B). 
No significant difference between the treatment groups was observed in the number of entries 
made to the wrong arms of the maze (Figure 4.5 C). Memory recall was assessed a week after 
the end of acquisition phase, and pathlength, velocity and number of errors were measured. All 
the readouts were comparable to those obtained during the acquisition. No significant 
difference between the groups was observed in any of these readouts (Figure 4.5 D, E and F), 
indicating that all animals remembered the task and position of the platform. The reversal 
phase of radial arm water maze was carried out the next day, wherein cognitive flexibility was 
measured by moving the target platform to a different arm. Pathlength, velocity and errors 
were quantified (Figure 4.5.G, H, I). No significant difference was observed between the 
groups during the reversal phase indicating all animals unlearned the old position of the 
platform and relearned the new one. In female mice, both the groups exhibited a similar 
pathlength, velocity and number of errors during the acquisition phase. During the memory 
probe and reversal trials phases, no significant difference was observed between the groups, 
indicating that female animals did not exhibit learning and memory deficits (Figure 4.6 A-I). 
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Figure 4.5. Assessment of spatial learning and memory using the radial arm water maze, in male 
mice after inducing aIGFR deficiency. Astrocytic IGFR deficiency does not alter spatial learning 
and memory in male mice. Animals were acclimated to the maze and the target platform for 30 
seconds before the start of the first trial on Day 1. Each trial consisted of 80 seconds. Pathlength, 
velocity and number of errors to first visit to the target were recorded during each trial. (A-C) 
Pathlength, velocity and total errors respectively measured on days 1-3 (acquisition phase) (The 
data is represented as mean±SE of 15 animals, two-way repeated measures ANOVA). (D-F) 
Pathlength, velocity and total errors respectively measured on day 10 (probe phase) (The data is 
represented as mean±SE of 15 animals, t-test). (G-I) Pathlength, velocity and total errors 
respectively measured on day 11 (reversal phase) (The data is represented as mean±SE of 15 




Figure 4.6. Assessment of spatial learning and memory using the radial arm water maze, in 
female mice after inducing aIGFR deficiency. Astrocytic IGFR deficiency does not alter spatial 
learning and memory in female mice. Animals were acclimated to the maze and the target 
platform for 30 seconds before the start of the first trial on Day 1. Each trial consisted of 80 
seconds. Pathlength, velocity and number of errors to first visit to the target were recorded 
during each trial. (A-C) Pathlength, velocity and total errors respectively measured on days 1-3 
(acquisition phase) (The data is represented as mean±SE of 20 animals, two-way repeated 
measures ANOVA). (D-F) Pathlength, velocity and total errors respectively measured on day 10 
(probe phase) (The data is represented as mean±SE of 20 animals, t-test). (G-I) Pathlength, 
velocity and total errors respectively measured on day 11 (reversal phase) (The data is 
represented as mean±SE of 20 animals, two-way repeated measures ANOVA). 
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In order to replicate the findings previously reported in literature (Logan et al., 2018), 
we assessed the number of revisits to the non-target arm as a measure of working memory. 
(Figure 4.7. A). However, this difference was not significant. To replicate the observation 
reported previously, working memory errors on day two was assessed separately but was not 
significant (Figure 4.7 B). In the reversal phase, no significant difference was observed 
between groups (Figure 4.7 C). In female mice, no differences between groups in working 
memory were observed in the acquisition or reversal phases (Figure 4.8 A-C). We also did not 




Figure 4.7. Assessment of spatial working memory using the radial arm water maze, in male 
mice after inducing aIGFR deficiency. Astrocytic IGFR deficiency does not alter spatial 
working memory in male mice. Animals were acclimated to the maze and the target platform 
for 30 seconds before the start of the first trial on Day 1. Each trial consisted of 80 seconds. 
Pathlength, velocity and number of errors to first visit to the target were recorded during each 
trial. A) Non-target errors or revisits to the same arm measured on days 1-3 (acquisition phase) 
(The data is represented as mean±SE of 15 animals, two-way repeated measures ANOVA). B) 
Working memory errors or revisits measured on day 2 of acquisition phase (The data is 
represented as mean±SE of 15 animals, t-test). C) Working memory errors measured on day 11 




Figure 4.8. Assessment of spatial working memory using the radial arm water maze, in female 
mice after inducing aIGFR deficiency. Astrocytic IGFR deficiency does not alter spatial 
working memory in female mice. Animals were acclimated to the maze and the target platform 
for 30 seconds before the start of the first trial on Day 1. Each trial consisted of 80 seconds. 
Pathlength, velocity and number of errors to first visit to the target were recorded during each 
trial. A) Non-target errors or revisits to the same arm measured on days 1-3 (acquisition phase) 
(The data is represented as mean±SE of 20 animals, two-way repeated measures ANOVA). B) 
Working memory errors or revisits measured on day 2 of acquisition phase (The data is 
represented as mean±SE of 20 animals, t-test). C) Working memory errors measured on day 11 
(reversal phase) (The data is represented as mean±SE of 20 animals, two-way repeated 
measures ANOVA)  
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To confirm our findings from the radial arm water maze, we used the Barnes maze 
which has been traditionally used in assessing spatial learning and memory. Traditional 
readouts like pathlength, velocity and latency were assessed. Male aIGFR-KO showed a 
similar pathlength and latency as the control mice (Figure 4.9 A and C). However, they 
exhibited a higher velocity as compared to control mice (Figure 4.9 B). Memory recall was 
performed on Days 5 and 10. No significant difference was observed between the groups in 
pathlength, velocity and latency (Figures 4.9 D-I). During the reversal phase too, male aIGFR-
KO mice exhibited similar pathlength, velocity and latency to control mice (Figures 4.9 J-L). 
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Figure 4.9. Assessment of spatial learning and memory using the Barnes maze, in male mice 
after inducing aIGFR deficiency. Astrocytic IGFR deficiency does not alter spatial learning and 
memory in male mice. Animals were acclimated to the maze and the escape box platform for 30 
seconds before the start of the first trial on Day 1. Each trial consisted of 90 seconds. Pathlength, 
velocity and number of errors to first visit to the target were recorded during each trial. (A-C) 
Pathlength, velocity and total errors respectively measured on days 1-4 (acquisition phase) (The 
data is represented as mean±SE of 15 animals, two-way repeated measures ANOVA). (D-F) 
Pathlength, velocity and total errors respectively measured on day 5 and (G-I) on day 10 (probe 
phases) (The data is represented as mean±SE of 15 animals, t-test). (J-L) Pathlength, velocity and 
total errors respectively measured on day 11 (reversal phase) (The data is represented as 
mean±SE of 15 animals, two-way repeated measures ANOVA). 
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In females, no difference between groups was observed in pathlength, velocity or 
latency during the acquisition, probe or reversal phases in the Barnes maze (Figure 4.10). All 
the animals learned the task and remembered the position of the escape box. Taken together, 




Figure 4.10. Assessment of spatial learning and memory using the Barnes maze, in female mice 
after inducing aIGFR deficiency. Astrocytic IGFR deficiency does not alter spatial learning and 
memory in femmale mice. Animals were acclimated to the maze and the escape box platform for 
30 seconds before the start of the first trial on Day 1. Each trial consisted of 90 seconds. 
Pathlength, velocity and number of errors to first visit to the target were recorded during each 
trial. (A-C) Pathlength, velocity and total errors respectively measured on days 1-4 (acquisition 
phase) (The data is represented as mean±SE of 20 animals, two-way repeated measures 
ANOVA). (D-F) Pathlength, velocity and total errors respectively measured on day 5 and (G-I) 
on day 10 (probe phases) (The data is represented as mean±SE of 20 animals, t-test). (J-L) 
Pathlength, velocity and total errors respectively measured on day 11 (reversal phase) (The data 
is represented as mean±SE of 15 animals, two-way repeated measures ANOVA).
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4.4.5. Astrocytic IGFR deficiency does not cause anxiety-like behavior 
To assess the anxiety-like behavior in mice, elevated plus maze was utilized. Time spent by 
the mice in open-arms and closed arms was quantified during a 5-minute trial in the maze. 
No significant difference was observed between groups in both male and female cohorts 
(Figure 4.11 A and B). Additionally, the time spent in center and periphery was also 
quantified using the open field apparatus as an indicator of anxiety-like behavior. We 
observed no difference in the groups (Figure 4.11 C and D) indicating that astrocytic IGFR 
deficiency does not result into an anxiety-like phenotype. 
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Figure 4.11. Assessment of anxiety-like behavior using the elevated plus maze and open field 
testing apparatus after inducing aIGFR deficiency. Astrocytic IGFR deficiency does not induce 
anxiety-like behavior in mice. Animals were placed in the center of the elevated plus maze 
facing an open arm for 5 minutes. Percentage of time spent in closed and open arms was 
recorded during the trial. In the open field apparatus, percentage of time spent exploring the 
center and periphery was calculated. A) Percentage of time spent in open arms of the elevated 
plus maze by males (The data is represented as mean±SE of 15 animals, t-test B) Percentage of 
time spent in open arms of the elevated plus maze by females (The data is represented as 
mean±SE of 20 animals, t-test) percent time spent in the center of the open field test apparatus 
(C) Percentage of time spent in the center of the open field apparatus by male mice (The data is 
represented as mean±SE of 15 animals, t-test) D) Percentage of time spent in the center of the 
open field apparatus by females. (The data is represented as mean±SE of 20 animals, t-test). 
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4.4.6. Astrocytic IGFR deficiency does not result into depressive phenotype in mice 
To assess depression-like behavior, the tail suspension test was performed. Two different 
measures were calculated, namely the latency to first give up and latency to complete 
immobility. In males, the latency to first give up was observed to be significantly higher in 
aIGFR-KO than the control group (Figure 4.12 A), but the final latency to immobility is not 
significantly different (Figure, 4.12 B) indicating the absence of a depressive phenotype. In 
females, the latency to immobility as well as latency to first give up are not significantly 
different (Figure 4.12 A and B). Thus, the data indicate that astrocytic IGFR deficiency does 
not induce an anxiety-like or depressive phenotype in mice. 
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Figure 4.12. Assessment of depression-like behavior using the tail suspension test after 
inducing aIGFR deficiency. Astrocytic IGFR deficiency does not induce depression-like 
behavior in mice. Animals were suspended by the tail for 5 minutes. Latency to first stop trying 
to straighten up and latency to complete immobility was recorded. A) Latency to first give up in 
male mice. B) Latency to complete immobility in male mice (The data is represented as 
mean±SE of 15 animals, t-test (C) Latency to first give up in female mice. D) Latency to 
complete immobility in female mice. (The data is represented as mean±SE of 20 animals, t-
test). 
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4.4.7. Knockdown of astrocytic IGFR increases the levels of glutamate in the brain and alters 
the genes associated with glutamate-glutamine cycling 
To investigate the potential changes in the brains of aIGFR-KO animals, of certain crucial 
amino acids were quantified in the brains of male aIGFR-KO mice. Levels of glutamate in the 
brain were significantly higher with aIGFR reduction (Figure 4.13A). However, levels of 
glutamine, aspartic acid and glycine were not significantly different (Figure 4.13 B-D). Other 
excitatory amino acids in the brain were also measured, no significant change was observed 
(Figure 4.13 E). 
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Figure 4.13. Assessment of levels of various amino acids in the brains of male mice. Astrocytic IGFR 
deficiency alters the level of glutamate, but not other amino acids in male mice. A hemisphere of 
the brain was processed and stabilized in a solution containing SSA. 100 µL of the processed lysate was 
sent to the Vanderbilt Core for assessment of hormones and amino acids. Levels of A) Glutamic acid B) 
Glutamine (C) Aspartic acid D) Glycine E) Other amino acids included threonine, serine, 
asparagine and alanine (The data is represented as mean±SE of 9 animals, t-test, * indicates 
p<0.05) 
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Next, the expression of all the neuronal and astrocytic genes involved in the regulation 
of glutamate-glutamine cycling was assessed in the cortices as well as hippocampi of these 
animals. It was observed that in males, some of the genes associated with glutamate receptor 
subunits- Grin 2c and Grm 7 are significantly downregulated in the hippocampus, but not in 
the cortex (Figure 4.14 A and B). A decrease in the expression of glutamine transporters on 
astrocytes (Slc38A3 and Slc38A5) in the hippocampi but not cortices was also seen. In 
females, a change in the levels of glutamate receptor subunit Grm7 and glutamate transporter 
Slc1A7 in the hippocampus but not cortex (Figure 4.15 A and B). 
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Figure 4.14. Assessment of genes associated with glutamate-glutamine cycling in the cortex and 
hippocampus. Astrocytic IGFR deficiency alters the level of genes associated with glutamate- 
glutamine cycling in male mice in A) Cortex B) Hippocampus. The data is normalized to 




Figure 4.15. Assessment of genes associated with glutamate-glutamine cycling in the cortex and 
hippocampus. Astrocytic IGFR deficiency alters the level of genes associated with glutamate- 
glutamine cycling in female mice in A) Cortex B) Hippocampus. The data is normalized to 
HPRT, YWHAZ and GAPDH. (The data is represented as mean±SE of 9 animals, t-test, * 
indicates p<0.05) 
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The expression of two main glutamate uptake transporters in the brain cortex EAAT 
1 and EAAT2 was also assessed. It was observed that EAAT2 levels were significantly 
lower in the aIGFR-KO animals. Expression of EAAT1 and GS was not significantly 
different between groups (Figures 4.16 A-C). Next, the activity of glutamine synthetase 
enzyme in the hippocampal tissue was assessed. No significant changes were observed in 
the activity of glutamine synthetase in male or female mice (Figure 4.16 D and E). Thus, 
our data indicate that knockdown of IGFR in astrocytes causes an imbalance of glutamate 
handling by dysregulating key proteins involved in glutamate uptake and cycling. 
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Figure 4.16. Assessment of expression of key transporter genes, responsible for glutamate 
uptake, and downstream enzyme GS. Astrocytic IGFR deficiency does not change the activity of 
glutamine synthetase but alters the expression of key glutamate transporter EAAT2 in mice A) 
Change in the expression of cortical EAAT1 transporter in mice B) Change in the expression of 
cortical EAAT2 transporter in mice. C) Change in the expression of cortical GS in mice. The data is 
normalized to HPRT, YWHAZ and GAPDH. D) GS activity assay in males E) GS activity assay in 
females (The data is represented as mean±SE of 9 animals, t-test, * indicates p<0.05) 
115
4.4.9. Knockdown of astrocytic IGFR causes does not cause changes in the expression of 
GFAP or astrocyte size and number. 
To assess astrogliosis in aIGFR-KO animals, astrocyte size, count and expression of 
GFAP was measured. Astrocyte size and count was assessed using immunohistochemical 
analysis of these brains. No significant difference was observed in astrocyte size or count in 
both male and female cohorts (Figure 4.17 and Figure 4.18) 
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Figure 4.17. Assessment of astrocyte number in the hippocampi after aIGFR reduction. 
Astrocyte number does not change in response to astrocytic IGFR deficiency. 
Immunohistochemistry was performed using 35 µ slices of brain. Rabbit polyclonal antibody 
against GFAP was used for staining and secondary Anti-rabbit Alexa 546 was used to visualize 
GFAP. A) Representative images and quantification of astrocyte count in the DG region of the 
hippocampus stained for GFAP in males. B) Representative images and quantification of 
astrocyte count in the DG region of the hippocampus stained for GFAP in females (The data is 
represented as mean±SE of 6 animals, t-test)  
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Figure 4.18. Assessment of astrocyte size in the hippocampi after aIGFR reduction. Astrocyte 
size does not change in response to astrocytic IGFR deficiency. Immunohistochemistry was 
performed using 35 µ slices of brain. Rabbit polyclonal antibody against GFAP was used for 
staining and secondary Anti-rabbit Alexa 546 was used to visualize GFAP. A) Representative 
images and quantification of astrocyte size in the DG region of the hippocampus stained for 
GFAP in males. B) Representative images and quantification of astrocyte size in the DG region 
of the hippocampus stained for GFAP in females (The data is represented as mean±SE of 6 
animals, t-test).  
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GFAP expression was assessed in the brains of male and female control and aIGFR-
KO animals. No significant difference was observed in the expression of GFAP between 
groups in male and female animals (Figure 4.19). Taken together, these data indicate that 
astrocytic IGFR dysregulation does not cause lead to astrogliosis. 
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Figure 4.19. Assessment of astrogliotic marker GFAP in the cortex after aIGFR reduction. GFAP 
expression does not change in response to astrocytic IGFR deficiency. Western Blotting was 
performed using cortical tissue lysates. A) Representative images and relative expression of 
GFAP in males. B) Representative images and relative expression of GFAP in females (The data 
is represented as mean±SE of 8 animals, t-test). All data  are normalized to GAPDH. 
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4.4.9. Knockdown of astrocytic IGFR causes changes in the expression of Caspases and 
increase in the levels of urea in the brain 
To examine the effects of astrocytic IGFR-KO on neuronal stress and astrocytic stress, 
we assessed the expression of their caspase 3 and 9 markers. In male aIGFR-KO mice, 
caspase 3 cleavage is significantly lower than the control mice, while that of caspase 9 is not 
different (Figure 4.20 A and B). In female aIGFR-KO mice, a significant decrease in caspase 
9 cleavage but not caspase 3 was seen (Figure 4.20 C and D). Thus, the data here indicate that 
aIGFR deficiency does alter caspase activation but it is not enough to initiate apoptotic 
cascade. Interestingly, we also observed an increase in the level of urea in the brains of 
aIGFR-KO animals. Upon this observation, we also assessed the levels of urea in the serum of 
these animals and observed no significant difference between the control and treatment 
groups. This indicated that the buildup of urea was higher in the brains of aIGFR-KO animals.   
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Figure 4.20. Assessment of apoptosis by caspase activation analysis in response to aIGFR 
deficiency. Astrocytic IGFR deficiency alters the cleavage of caspases but does not cause 
apoptosis. Caspase 3 and 9activation was assessed using western blotting in male and female 
mouse cortical tissue. Level of cleaved caspase was normalized to total caspase levels. A) 
Cleavage of caspase 9 in males B) Cleavage of caspase 3 in males C) Cleavage of caspase 9 in 
females D) Cleavage of caspase 3 in (The data is represented as mean±SE of 9-12 animals, t-
test, * indicates p<0.05) 
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Discussion 
IGF-1 has been extensively studied in the context of aging, cognition and several other 
neurological disorders. Several human as well as animal studies have examined the 
relationship between IGF-1, cognition and the aging brain. Despite that, the field has not come 
to a consensus yet regarding the role of IGF-1 in regulating cognition and aging. Based on 
some of the contradictory results reported, the relationship of IGF-1 and cognitive decline in 
aging and neurodegeneration is complex. This is because at a molecular level, several brain 
cell types express IGF-1 and IGFR both, and may respond differently in different pathologic 
conditions. As a result, it is important to understand the effect of declining IGF-1 signaling on 
individual brain cell types and how they respond to the change. The study described here was a 
step in that direction and addressed the key question of whether astrocytic IGFR signaling 
played an important role in contributing towards a cognitive decline associated with IGF-1 
deficiency. In summary, the results presented here suggest that loss of IGFR on astrocytes 
leads to a variety of molecular changes, altering the way astrocytes carry out their functions in 
regulating the brain microenvironment, thus increasing the susceptibility to cognitive decline.  
IGF-1 plays an important role in brain development and function. With age, as GH 
levels fall, levels of circulating IGF-1 also fall (Sonntag et al., 2005). This has been associated 
with cognitive decline in both humans and rodents. Traditionally, in addition to aged mice, the 
liver IGF-1 deficient mice exhibiting 60% decrease in circulating IGF-1 levels have been 
studied for cognitive deficits. The LID mice show an impairment in spatial learning and 
memory, similar to what is observed in aged animals. They also show impairment in LTP 
suggesting liver-derived IGF-1 plays an extremely important role in regulating the same (J. I. 
Trejo et al., 2007). 
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However, both male and female Ames Dwarf mice exhibit a completely normal 
performance in learning and memory tasks despite having both GH and IGF-1 deficiency 
(Kinney et al., 2001). Interestingly, these mice exhibited a high autocrine level of IGF-1, 
which was initially thought to be the reason they performed well in learning and memory 
tasks. LID mice which showed impaired spatial learning and memory, did not have autocrine 
IGF1 deficiency. Another study showed that IGF-1 levels in the CSF and brain tissues 
including the hippocampus go down with age (Ashpole et al., 2015). Recently, a study was 
published reporting that astrocytic IGFR deficiency causes impaired working memory in mice 
(Logan et al., 2018). Although interesting, this study has not addressed a lot of concerns. It 
utilizes radial arm water maze to assess spatial learning and memory in mice, but traditional 
readouts like pathlength, velocity and latency have not been reported. Additionally, a 
difference in working memory is reported based on the number of errors made on Day 2. The 
number of errors made on day 3 have not been reported. The appropriate statistical test to 
examine the differences in learning and memory using the radial arm water maze is a two-way 
repeated measures ANOVA. However, only a t-test was performed by them to analyze all of 
day 2 trials. Yet another limitation is that the study does not report sexes of the animals, which 
is quite surprising given the relationship between IGF-1 and cognitive decline has been shown 
to be sex-dependent in the literature. 
In an attempt to answer whether liver-derived IGF1 regulates cognition via astrocytes, 
we knocked down astrocytic IGFR after puberty to avoid any developmental effects associated 
with IGF-1 deficiency and assessed cognition in them. Our data obtained from the radial arm 
water maze indicates that aIGFR deficiency does not cause any impairment in learning, or 
memory in males. No difference is seen with Barnes maze either. In females, knockdown of 
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aIGFR does not cause any impairment in learning or memory either. General locomotion, 
muscle strength and motor coordination assessment show no differences in either males or 
females, indicating the effects of loss of circulating IGF1 deficiency on these behaviors are not 
mediated by astrocytes. A possible explanation for the absence of a larger effect on learning 
and memory could be compensatory effects due to Insulin signaling, or compensation by other 
growth factors like BDNF (Ding et al., 2006). 
In addition to learning and memory, loss of IGF-1 signaling is also known to affect the 
onset of depression in rodents as well as lead to an anxiety-like behavior (Burgdorf et al., 
2010; Patki et al., 2013). On the other hand, a few other studies report that IGF-1 does not 
regulate depression-like behavior (Tang Q. et al. 2014). Our data indicates that aIGFR-KO 
mice do not exhibit an anxiety-like or depression-like phenotype, supporting the fact that IGF-
1 does not regulate anxiety-like or depression-like behavior through astrocytes. Additionally, 
we also did not observe changes in gait as reported by previous studies, thus suggesting 
changes in gait due to loss of IGF1 signaling are not mediated by astrocytic IGFR (Doi et al., 
2015). 
Although we did not observe any major behavioral changes, we did see a number of 
molecular changes in the brain including those in the glutamate-glutamine cycling machinery 
genes. We also observed a global increase in the level of glutamate in these brains. As 
discussed in the previous chapters, several studies have reported a chronic increase in the 
levels of glutamate leading to excitotoxicity in several neurological disorders including aging 
and neurodegeneration. The data obtained from our male aIGFR-KO mice is consistent with 
our previous data from Chapter 2. 
To further examine the effect of loss of IGFR signaling on glutamate-glutamine 
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cycling in aIGFR-KO, we examined the expression and activity of an astrocyte-specific 
enzyme Glutamine Synthetase (GS). This enzyme converts the glutamate that is taken up by 
the astrocytes into glutamine and releases it back for neurons to utilize. Maintenance of the 
glutamate-glutamine cycle is critical for the preservation of brain microenvironment. Not only 
does this help clear the synapses of extra glutamate, but also enables the formation and supply 
of glutamine to the neurons. This is extremely crucial because neurons cannot make their own 
glutamine and rely exclusively on astrocytes to supply it to them (Sonnewald et al., 1997). 
Mutations or dysregulation in glutamine synthetase are implicated in several neurological 
disorders exhibiting glutamate neurotoxicity and dyregulated IGF-1 signaling including 
epilepsy (Bernard & Habash, 2009; Coulter & Eid, 2012; Eid et al., 2012). Our data indicate 
the astrocytic IGFR deficiency does not contribute to altered expression or activity of GS in 
aIGFR-KO animals. We examined all the components of the glutamate-glutamine cycling 
machinery, and observed a decrease in the expression of some ionotrophic as well as 
metabotrophic glutamate receptor subunits in these animals. In males aIGFR-KO animals, we 
also see a decrease in the expression of SNAT 5, a crucial transporter responsible for 
exporting glutamine synthesize in the astrocytes back to the neurons. Collectively, these data 
indicate an alteration in some crucial transporters including glutamate and glutamine, further 
supporting the fact that astrocytic IGFR is crucial for regulating aspects of glutamate-
glutamine cycle. 
Another observation made was that of the overall increase in the levels of urea in the 
brains of these mice. Studies in sheep and humans indicate that a chronic buildup of urea in 
the brain can be linked to dementia and neurodegenerative disorders like Huntington’s 
disease. Specifically, it is an indication of protein catabolism and energy deficit as seen with 
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mitochondrial dysfunction (Handley et al., 2017). Thus, our findings support the observation 
reported in some studies that astrocytic IGFR is important for regulation of mitochondrial 
function, also supporting the fact that astrocytic dysfunction could be one of the early 
changes happening in the brain before the development of a neurological disorder.  (Logan 
et al., 2018) 
To further assess astrocyte dysfunction, we assessed astrocyte count, size and 
expression of GFAP. GFAP is a key component involved in glial scar formation in response to 
injury. Also, GFAP expression in known to be upregulated with astrocyte dysfunction (Dossi 
et al., 2018). IGF-1 deficiency is also known to known to upregulate GFAP. Our data shows 
no changes in the expression of GFAP or abnormalities in astrocyte size and count. However, 
that does not eliminate the possibility that these abnormalities would be observed in the later 
stages of astrocyte dysfunction owing to IGF1 deficiency. 
Our data indicates that aIGFR-KO mice also exhibit an upregulation of caspase 9 in 
both males and females. In the intrinsic pathway of apoptosis, mitochondrial dysfunction 
triggers release of cytochrome c, which activates the cleavage of Caspase-9. Caspase 9 
ultimately activates cleavage of caspase 3 and amplification of response (Li et al., 2002). Our 
findings suggest that aIGFR knockdown and the associated molecular changes activate the 
intrinsic pathway of apoptosis. However, in females, activation of caspase 3 is not seen which 
is consistent with other behavioral and molecular data suggesting aIGFR knockdown may 
affect male mice more than females. 
One limitation of this study include difficulty to tease apart the IGF-1 versus INS 
signaling pathway contribution in the brains of these animals. Another limitation is that we 
did not assess the compensatory effects of other growth factors in the brain. Some future 
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directions include examining the effect of loss of IGF signaling in astrocytes in the context 
of other disease, studying the role of INS-IGF-1 hybrid receptor in pathology, and examining 
cognitive defects at a later age in mice.  
Although we assessed levels of blood urea and did not find a significant difference 
between the control and treatment groups, we did not assess the expression or activity of 
other enzymes involved in the ammonia detoxification system in the brain. Ammonia that 
enters the brain via several transporters is detoxified with the help of glutamate and 
glutamine synthetase, to produce glutamine. Glutamine is osmotically active and may cause 
swelling of cells if not exported properly to maintain the correct concentration in the 
glutamine pool. In addition to this, ammonia is also combined with alpha-keto glutarate for 
production of glutamate or entry into the TCA cycle, which was not assessed in this study. 
Failure in achieving this could lead to energy deficiency and mitochondrial dysfunction in 
urea cycle disorders. A buildup of urea due to any of the above mentioned factors would 
then affect the membrane potential in neurons, neurotransmitter signaling, impaired 
communication between cells and disruption of bioenergetics of the brain, contributing to the 
susceptibility of developing cognitive disorders (Gropman et al., 2007; Bosoi et al., 2008). 
Future studies should focus on exploring the role of IGF-1 and these critical enzymes that 
regulate brain ammonia metabolism. The effect of loss of astrocytic IGF-1 signaling on the 
enzymes like glutamate dehydrogenase that regulate the conversion of glutamate to GABA 
and vice versa, to maintain the balance between excitatory and inhibitory signaling in the 
brain. 
Conclusion 
Taken together, this study points towards the fact that astrocytic IGFR signaling is 
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extremely important in maintaining the brain microenvironment, and facilitating astrocytes to 
carry out their normal functions. Loss of astrocytic IGFR does not lead to a big change in 
spatial learning and memory, suggesting it is the neuronal IGFR that may be contributing to 
the learning and memory deficit in response to loss of IGF-1 signaling. However, astrocytic 
IGF-1 signaling is crucial for glutamate handling and the maintenance of the glutamate-
glutamine cycle. The changes observed may be the start of early pathologies contributing to 
astrocyte dysfunction and neurodegeneration eventually leading to cognitive decline. 
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CHAPTER 5. GENERAL CONCLUSIONS AND DISCUSSION 
5.1. Aging and cognitive decline 
Tremendous advances have been made in the field of medicine and healthcare to promote 
longer lifespan, making a large proportion of the global population to be susceptible to age-
associated diseases and disorders. Aside from the financial and emotional burden and loss of 
independence, loss of spatial learning and memory, reduced processing speed and inductive 
reasoning poses a challenge for aged individuals. As discussed before, not all aged individuals 
experience a drastic loss of cognition. Moreover, this cognitive decline is not uniform in terms 
of functions affected. Some individuals show impaired executive functions, while others show 
impaired episodic memory. (Glisky, 2019; Glisky et al., 1995; Wisdom et al., 2012). Some 
studies in rodents suggest that cognitive decline is reversible. However, the mechanisms are still 
not fully understood (Lichtenwalner et al., 2001; Markowska et al., 1998; Nishida et al., 2011; 
Pardo et al., 2018, 2016). Research interventions exploring why some aged individuals 
experience a drastic cognitive decline, while others do not, are needed in order to arrest or 
reverse cognitive decline in those that do. 
Contrary to the previous notion that cognitive decline is always accompanied by a loss 
of neurons or neuronal death, it is now well known that other changes occurring in the brain also 
contribute to cognitive impairment. These include, but are not limited to dysregulated
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synaptic signaling, disrupted brain bioenergetics, altered synthesis and release of signaling 
molecules, and changes in overall cellular structure, function and brain volume (Raz et al., 1998; 
Terry & Katzman, 2001). Although extensive research has been done in these areas, the molecular 
changes and mechanisms involved in causing cognitive decline still need to be explored further. 
Circulating factors like IGF-1 that are known to influence brain function, are susceptible to 
changes with aging and have been correlated to the extent of cognitive decline associated with age 
(Ashpole et al., 2015). 
5.2. IGF-1 and cognitive decline 
Insulin-like growth factor-1 (IGF-1) has been studied for the past 40 years for its 
influence on development, growth of organs and regulation of cognition. IGF-1 decline or 
deficiency has been correlated with the extent of cognitive decline in humans as well as several 
animal models. However, numerous disparities in experimental observations have been reported 
leading to the debate of whether IGF-1 is beneficial or detrimental to the aging brain (as 
reviewed by (Gubbi et al., 2018)). While it is not possible to underpin the development of 
cognitive decline by any one pathway or mechanism, it is evident that most of the studies till 
date have a neuron-centric approach and do not take into account the influence of IGF-1 on other 
brain cell types like astrocytes responsible for regulating the overall brain microenvironment. 
5.3. IGF-1 and astrocytes 
A number of studies have shown that astrocytes produce IGF-1 as well as express 
IGFR, and are involved in mediating neuroprotective effects against oxidative stress and brain 
injury in cultured cells as well as animals (Genis et al., 2014; Madathil et al., 2013). It also 
stimulates glucose uptake and regulates mitochondrial function in culture (Hernandez-Garzón 
et al., 2016; Logan et al., 2018). Addionally, applying IGF-1 exogenously upregulates GLAST 
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(EAAT1), one of transporters responsible for uptake of extracellular glutamate in the brain 
(Suzuki et al., 2001). Glutamate is one of the major neurotransmitters in the brain taking part 
in neuronal communication, excitability and synaptogenesis, ultimately contributing to the 
process of regulating cognition (Mattson, 1996; Shepherd & Huganir, 2007). In several 
neurological diseases with altered IGF-1 levels, and impaired cognition, disrupted glutamate 
buffering is also observed (Deak & Sonntag, 2012; Markowska et al., 1998; Vincent et al., 
2004). Additionally, IGF-1 deficiency has also been linked with astrogliosis or astrocyte 
reactivity (Dusart & Schwab, 1994; Latov et al., 1979). Thus, astrocyte dysfunction, and 
impaired cognition can be associates with IGF-1 deficiency. Based on these previously 
reported observations, we hypothesized that IGF-1 deficiency disrupts the ability of astrocytes 
to buffer glutamate, dysregulates glutamate- glutamine cycling, and ultimately alters 
cognition. 
5.4. IGF-1 and astrocytic function 
Astrocytes are dynamic cells that undergo structural and functional changes in response 
to the changing demands of the nervous system. Some of their functions include buffering of 
extracellular ions like K+, release of trophic factors and gliotransmitters, modulation of immune 
responses in conjunction with microglia, regulating the permeability of BBB, scar formation in 
injury, neurogenesis, synaptogenesis and synaptic transmission as reviewed in literature 
(Parpura & Haydon, 2009; Sofroniew & Vinters, 2010). One of the major functions of astrocytes 
is uptake of extracellular glutamate. In a tripartite synapse, astrocytes are involved with the 
clearance of glutamate via the glutamate uptake transporters EAAT1 and EAAT2. Glutamate 
uptake further dictates its conversion to glutamine, and the supply of glutamine back to the 
neurons. Additionally, some glutamate is also shuttled into the TCA cycle (Schousboe, Scafidi, 
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Bak, Waagepetersen, & McKenna, 2014). 
A previous study showed that IGF-1 transiently upregulates the expression of EAAT1, 
one of the transporters of glutamate (Suzuki et al., 2001). They report this change after a period 
of 36 hours of treatment, going back to baseline after an additional 24 hours. Our study supports 
the observation that a decrease in IGF-1 signaling reduces uptake of glutamate. However, it 
differs slightly from this one, in that we see a reduction in the trafficking of GLAST (EAAT1) 
to the cell surface with a 2-hour inhibition of IGFR, and a decrease in the expression of GLT-1 
(EAAT2) mRNA after 24 hours. (Prabhu, Khan, Blackburn, Marshall, & Ashpole, 2019). The 
key point to note here is that in humans, EAAT2 is responsible for taking up 90% of extracellular 
glutamate, while EAAT1 is responsible for only taking up 10% of it (Kim et al., 2011). Thus, 
our data also elaborate on the effects of short-term and long-term deficiency of IGF signaling on 
glutamate handling by astrocytes via transient as well as long-term changes. 
When astrocytes are chronically stressed, instead of taking up glutamate, they release 
glutamate in the extracellular space. Studies have shown that there are several mechanism of 
glutamate release, some of which include exocytosis via calcium-dependent fusion of vesicles 
to the membrane, release via purinergic receptor signaling, swelling of astrocytes and opening 
of anionic transporters, hemi channels, reversal of uptake transporters, and others (Malarkey & 
Parpura, 2008; Pang et al., 2018). When this delicate homeostatic balance between glutamate 
uptake (to regulate the extracellular concentrations) and release (to serve as a gliotransmitters), 
is disrupted, the astrocytes no longer serve a protective role as reviewed in the literature (Mahan, 
2019). Instead, they become reactive and contribute to conditions of excitotoxicity as their ability 
to respond to physiological signals like ATP, serine, calcium, etc. is disrupted. Our findings 
support this by showing an increase in the release of glutamate in cultured astrocytes in response 
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to a long-term deficiency of IGF1 signaling, in response to physiological stimuli like 200 µM 
ATP. This further strengthens the notion that astrocytes under a continued deficiency of IGF-1 
signaling will lose their ability to buffer glutamate homeostasis and protect the brain from 
excitotoxicity. Interestingly, the notion that an astrocyte doesn’t just exhibit a protective and a 
disruptive phenotype in the brain, but exists on activated astrocyte spectrum, has come into 
limelight (Halassa, Fellin, & Haydon, 2007). This opens new avenues for research that explores 
modulation of this spectrum in order for pathogenic astrocytes to become protective again by 
reversing some of the unwanted characteristics of the cell, while promoting those that are 
protective. 
5.5. IGF-1 and regulation of astrocytic structure 
As discussed previously, astrogliosis is accompanied by structural and functional 
changes in astrocyte that promote the slow but steady transition from a normal healthy astrocyte 
to a scar forming one in response to injury. The purpose of astrogliosis is adapt to the CNS 
insult, release molecules that can help heal the injury, but under certain circumstances this lead 
to harmful consequences. In a nut shell, astrogliosis is the adaptation of astrocytes in response 
to CNS injury involving generation of physical barrier or scar formation, production and release 
of molecules, and changes at the structural level to induce loss or gain of functions (Sofroniew, 
2015). Studies have shown previously that IGF-1 deficiency can lead to astrogliosis (Dusart & 
Schwab, 1994; Latov et al., 1979). Some of the preliminary data obtained in our lab from aged 
liver IGF deficient mice exhibited impaired learning and memory also showed increased GFAP 
expression too. Therefore, we wanted to explore a possible link between astrogliosis, IGF-1 
deficiency and astrocyte structure. In addition to disruption in the function, we also observed 
clustering of astrocytes treated with 5 µM PPP, and stained for structural proteins like Actin. 
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On the basis of these visual changes that appeared with multiple replicates, we questioned 
whether there was a change in structure and distribution of astrocytes similar to what is observed 
during scar formation in the event of an injury. Interestingly, in addition to the changes in actin, 
we also observed simultaneous changes in the S100β.  
S100β is a molecule predominantly expressed in astrocytes, and released in response to 
damage in response to invasion by pathogens, and is also implicated in the inflammatory 
processes in several neurological disorders like stroke, CNS injury, and neurodegenerative 
disorders. Despite its non-specificity, it has been explored as a biomarker in several studies as 
reviewed in the literature (Yardan, Erenler, Baydin, Aydin, & Cokluk, 2011). S100β serves a 
protective role at low concentrations, but exerts toxic effects at high concentrations. Among the 
many molecular changes associated with S100β signaling, one study reported that S100β 
regulates astrocyte shape and migration via the activity of Src kinase. Reducing S100β levels in 
astrocytes causes an increase in GFAP, collapsing of actin fibers onto the plasma membrane, 
reduces the migration of astrocytes and causes them to assume a stellate structure. Addionally, 
it also increases the differentiation potential of a cell by reducing the downstream activation of 
Akt and RhoA, the effectors of phosphatidylinositol 3-kinase (PI3K), simultaneously decreasing 
the activity of the RhoA-associated kinase (ROCK). (Brozzi, et al., 2009) As discussed in the 
previous chapters, IGF-1 signaling is capable of activating the PI3K/Akt pathway in astrocytes. 
Based on these findings, and the visual alterations we observed, we hypothesized that deficiency 
of IG1-1 signaling may be involved in causing the changes in structure and distribution of S100β 
and actin via the RhoA-ROCK cascade. Addionally, based on our previous results, we wanted 
to explore the effects of calcium blockade on the distribution changes in S100β, as disrupted 
glutamate handling would dysregulate calcium fluxes, thereby altering the distribution of S100β. 
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On quantification of the visual changes with manual scoring as well as software-based 
Pearson’s correlation coefficient analysis, no significant differences or correlations between 
S100β and concentration or duration of PPP treatment, with or without calcium blockade. 
Addionally, when the surface area on the cover slip not occupied by the clusters of cells was 
quantified, no differences between treatment groups were found. An important limitation in 
these set of experiments is the method of quantification and analysis of altered S100β 
distribution. In some of the older studies, scientists have relied on reporting visual changes 
(without scoring manually) alone. However, recent studies have taken into account the 
subjectivity of scoring and analyzed data using more reliable ways that involve manual scoring 
by more than 1 person blinded to the study, as well making use of sophisticated software like 
cell profiler, IHC profiler and other microscopy software like ImageJ and Nikon Elements for 
measuring Pearson’s correlation coefficient. With cultured cells clustered so tightly on top of 
each other on a coverslip, analysis of Pearson’s correlation coefficient poses a problem. This is 
because the software may detect the intensities of the dyes staining cells in multiple layers than 
a single layer. If the cells are plated at a lower confluence, analysis of Pearson’s correlation 
coefficient could possibly be used. Addionally, a more reliable way of obtaining data on changes 
in distribution of S100β in astrocytes would involve time-lapse imaging of its distribution. This 
can be achieved by transfecting astrocytes to express GFP-tagged S100β protein. This would 
give a real-time measurement of changes in S100β, after which data may be assessed using cell 
profiler or fractional proliferation analysis as mentioned in chapter 3. Addionally, for analysis 
of distribution, the intensity of S100β can be quantified within a zone drawn around a nucleus 
and a larger zone of a certain radius around it. Analysis of the expression levels of RhoA and 
ROCK, and phosphorylation of Akt showed no changes short-term or long-term, thereby 
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indicating IGF-1 deficiency does not alter astrocyte structure via the RhoA-ROCK cascade. In 
the future extracellular matrix modifying molecules released by astrocytes in response to 
astrogliosis or injury should be assessed. 
5.6. IGF-1 and astrocytic regulation of cognition 
The effects of IGF-1 on cognition have been studied using numerous models with 
disruptions in the GH/IGF-1 axis. However, there is a lot of controversy associated with the 
role of IGF-1 signaling in age-associated cognitive decline. Some studies in older adults have 
reported that decline in IGF-1 levels are associated with cognitive decline (Deijen et al., 1998; 
Doi et al., 2015; Kołtowska-Häggström et al., 2006; Lijffijt et al., 2003; Wennberg et al., 2018). 
Additionally, this cognitive decline can be ameliorated by supplements of GH or IGF-1 or both 
(Deijen et al., 1998; Golgeli et al., 2004; Oertel et al., 2004). On the other hand, some studies 
show an inverse or no association of IGF-1 levels and cognition (Green et al., 2014; Perice et 
al., 2016; Tumati, et al., 2016). Interestingly, there exists a sex-dependence on the relationship 
between IGF-1 levels and cognition, with a number of studies reporting that IGF-1 deficiency 
could be beneficial in females but not males (Green et al., 2014; Okereke et al., 2007). In rodent 
models, a similar disparity in the data has been reported with respect to cognition. Studies show 
that Ames dwarf mice exhibit a circulating GH and IGF-1 deficiency. However, they exhibit 
better health span, lifespan and normal cognitive function compared to their age-matched 
controls throughout life (Bartke & Brown-Borg, 2004; Kinney et al., 2001; Sonntag et al., 
2005). On the other hand, some studies report an association of loss of IGF-1 and cognitive 
decline, and that restoration of GH or IGF-1 levels ameliorates it (Markowska et al., 1998; 
Sonntag et al., 2000; Thornton et al., 2000; Toth et al., 2015; Trejo et al., 2007). These 
controversial results are difficult to interpret not only because they have been obtained from 
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different models, with different onsets of loss of IGF-1 signaling, different sexes, different 
experimental design and different endpoints. Thus, it is pertinent to study the pleiotropic effects 
of IGF-1 signaling in cognition and aging/neurodegeneration at a molecular level, keeping in 
mind the dynamics of brain milieu, particularly how each brain cell type contributes to cognitive 
decline in conditions of IGF1 deficiency. For this, cell-specific knockout of IGF1 or IGFR can 
be generated to examine the regulation of IGF1 signaling on that cell-type, and how that cell-
type responds to IGF-1 deficiency. 
Several studies have made use of a cell-specific IGF1 or IGFR knockout to examine the 
relationship of IGF-1 signaling and the disorder being studied. Cell-specific IGF-1 mutations 
in the liver and pancreatic beta cells affects metabolism and causes insulin resistance (Kulkarni 
et al., 2002; Sjögren et al., 1999). Knocking down IGFR in macrophages causes phenotypical 
changes in the macrophages and insulin resistance in mice (Spadaro et al., 2017). Knock down 
of IGFR1 in thyrocytes in male mice leads to reduced activity and locomotion, but not in female 
mice, with no anxiety-like behavior in either (Müller et al., 2011). For assessing cognitive- 
decline associated with loss of circulating IGF-1, the model that has been extensively 
characterized is the liver-specific IGF-1 deficient (LID) mouse. With a 60-70% reduction in 
circulating IGF-1 levels after IGF-1 is knocked down, LID mice exhibit a deficit in learning 
and memory, as well as impaired long-term potentiation (Trejo et al., 2007). LID mice also 
exhibit an anxiety-like and a depressive phenotype (Burgdorf et al., 2010). Not surprisingly, 
aged LID mice show impaired spatial learning and memory, impaired metabolism and 
mitochondrial function (Pharaoh et al., 2019) 
To better understand the relationship between cognition, age, sex and onset of IGF-1 
deficiency, a study performed in mice with liver-specific igf deficiency induced in the post-natal, 
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early and late-adulthood periods of life. This study showed that low IGF-1right from early stages 
of life, causes an increase in life span but not health span in female LID mice. Overall, IGF-1 
deficiency in late adulthood was detrimental to lifespan as well as health span. Additionally, 
these mice also showed impaired gait and decreased muscle strength. (Ashpole et al., 2017). A 
number of studies have reported sex-specific effects of targeting either IGF-1or IGFR, 
improving health span as well as life-span but only in female mice, highlighting the interaction 
between IGF-1 and sex (Bokov et al., 2011; Mao et al., 2018). 
The effects of loss of IGF-1 signaling on cognition may be mediated by neurons and 
other cell types together in the brain. Knockdown of IGF-1 specifically in the neurons causes 
behavioral deficits including depression, abnormal exploratory behavior, and microcephaly 
(Kappeler et al., 2008; Mitschelen et al., 2011). Preliminary evidence from our lab also indicates 
impaired spatial learning and memory in neuron-specific IGFR knockout mice (unpublished). 
Based on these observations, and our results from in vitro experiments, we questioned whether 
astrocytes played a role in the cognitive decline associated with IGF-1 deficiency. We 
hypothesized that mice with astrocytic IGFR deficiency would exhibit impaired spatial learning 
and memory, and an anxiety-like or depressive phenotype. A study recently showed that 
deficiency of astrocytic IGFR impairs working memory, metabolism and disrupts amyloid beta 
uptake (Logan et al., 2018). As discussed in the previous chapter, this study does not report the 
sex-dependence of IGF-1 signaling on cognition, which is clearly highlighted in most of the 
clinical as well as animal studies till date. Addionally, the study has not reported some of the 
traditionally measured readouts of spatial learning and memory assessment. In our study, we 
have bridged this gap by conducting a thorough assessment of numerous cognitive behaviors 
and examining the sex-dependence of IGF-1 regulation of cognition. Contrary to what was 
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published in the (Logan et al., 2018) study, we only observe a slight impairment in learning, but 
not memory. Most importantly, this is only seen in males and not females. We also do not 
observe any significant changes in working memory in these animals. Additionally, there is no 
change in the general locomotion, grip strength or motor coordination in these mice as discussed 
in the previous chapter. Taken together, these data indicate that the cognitive decline with loss 
of IGF-1 signaling is for the most part not mediated by astrocytic IGFR. 
Although we do not see any major changes in cognition in the aIGFR-KO mice, we do 
see an overall increase in the levels of glutamate, and aspartic acid. We also observe a decrease 
in the level of key glutamate-glutamine cycle associated proteins. Additionally, we also observe 
an increase in the brain urea levels and activation of caspases. Thus, our data indicates that 
astrocytic IGFR signaling is not directly involved in mediating cognitive decline. However, a 
reduction in its signaling will increase the susceptibility of an individual to develop cognitive 
decline. A schematic describing the results of this study and the proposed future directions is 
shown in Figure 5.1. 
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Figure 5.1. Schematic representation of conclusions and future directions. Astrocytic IGFR 
deficiency does not significantly affect structure. It disrupts one of the major functions of 
astrocyte- the uptake of glutamate by decreasing the expression or availability of glutamate uptake 
transporters. This would eventually lead to the over activation of AMPA and NMDA glutamate 
receptors, allowing increased sensitivity to excitation by prolonged depolarization of cells. This 
would eventually lead to release of calcium from various calcium stores and lead to over activation 
of several kinases and proteases that would ultimately prove to be neurotoxic. Addionally, 
mitochondrial enzymes particularly sensitive to calcium would trigger the initiation of apoptotic 
cascades in the cell, eventually leading to cell death. This would increase the susceptibility to 
develop cognitive decline. Thus, future studies should examine the role of aIGFR signaling in the 




Limitations of the study: 
Our conditional knockout (aIGFR-KO) mice have been generated by targeting GFAP 
expressing cells in the body. In the CNS, this would target astrocytes in the different regions of 
the brain including the hippocampus, cortex, cerebellum, as well as spinal cord. Although 
astrocytes are the major type of GFAP expressing cells in the brain, they are not the only GFAP 
expressing cells in the body. During development, ependymal cells that form a part of the Blood- 
CSF barrier, also express GFAP (Roessmann et al., 1980). However, since these conditional 
knockouts have been generated after development, a contribution of ependymal cells to the 
behavioral phenotype that we observe is not likely to occur. After development, GFAP has been 
shown to be expressed in Schwann cells, bone marrow stromal cells, chondrocytes, and in 
fibroblasts of dura mater, skull and spinal perichondrium, and periosteum, connective stroma of 
oral cavity, dental pulp, and cardiac valves (Hainfellner et al., 2001). Thus, our GFAP driven Cre 
would cause IGFR deficiency and disrupting IGF-1 signaling in these tissues. Since IGF1 
signaling promotes the health and function of these cells, IGFR reduction in these cells may lead 
to unwanted effects on aspects of health other than cognition. 
The retina of the eye also contains astrocytes. We wanted to see if deficiency of IGFR in 
the astrocytes of the retina would make the animals be more susceptible to developing blindness. 
However, vision test was performed to assess blindness and these animals were found to have no 
visual impairment. In addition to the retina, in mice, Leydig cells of testes express GFAP (Ortega 
etal., 2004). It has been speculated that due to expression of GFAP as well as some neuronal 
markers, and synaptic proteins in the Leydig cells of the testes, these cells assume some functions 
or phenotype similar to neuroendocrine cells, and may even engage in some type of paracrine 
signaling for steroidogenic regulation. Leydig cells may influence the contractile activity of the 
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smooth muscle cells of blood vessels, thus regulating the blood flow rate and the permeability for 
hormones and nutritive substances. Also, Leydig cells may play a role in regulating the Sertoli 
cells and germ cells of the seminiferous tubules (Davidoff et al., 1996; Davidoff et al., 2002). IGF-
1 is shown to regulate the proper testes growth and sperm production (Pitetti et al., 2013). In 
addition to that, it has also been shown to regulate the secretion of testosterone by Leydig cells 
(Baker et al., 1993). Testosterone has been widely known to influence behavior in mice including 
spatial learning and memory, physical activity, anxiety and depression (Celec, et al., 2015). This 
may lead to confounding effects of off-target IGFR deficiency on behavior in males. 
Another potential limitation would be compensatory changes occurring in the levels of 
IGF-1 in the serum or CSF in response to knockdown of astrocytic IGFR. We performed the IGF-
1 ELISA to examine the compensatory changes in IGF-1 levels in the serum, and none were 
observed. However, we did not measure the levels of IGF-1 in CSF. Studies have shown that IGF-
1 from the circulation can cross the BBB or the Blood-CSF barrier (Beilharz et al., 1998; 
Nishijima et al., 2010). It can then bind to the insulin receptors or hybrid receptors to initiate 
similar signaling pathways leading to compensatory effects in the brain (Boucher et al., 2010). 
Insulin signaling itself may be upregulated as a compensatory response. Our study did not assess 
this. 
A different type of compensation would involve upregulation of other growth factors in 
the brain against IGFR deficiency in astrocytes. A study showed an increase in the levels of Brain-
derived neurotrophic factor (BDNF) mRNA in the hippocampi of animals in response to liver-
derived IGF-1 deficiency, CA1 IGF-1 deficiency, or both (Mitschelen et al., 2011). BDNF is a 
growth factor secreted by several cell types in the brain including astrocytes. It regulates synaptic 
plasticity and plays a precognitive role by exerting anti-depressant, anxiolytic effects and 
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improvement in spatial learning and memory (Griffin et al., 2011; Kernie, 2000; Lee & Kim, 
2010; Mizuno et al., 2000; Monteggia et al., 2007; Schmidt & Duman, 2010). A number of studies 
have established that BDNF mRNA is upregulated in response to IGFR blockade (Ding et al., 
2006). With a deficiency of astrocytic IGFR receptors, some compensatory effect may be 
occurring in terms of upregulation of BDNF by astrocytes or neurons or both, ultimately 
influencing behavior. However, whether that has an effect on behavioral phenotypes needs to be 
assessed further.  
Future Directions: 
A model for studying other neurological disorders 
As reviewed in chapters 1 and 2, disrupted IGF1 signaling is a feature of several 
neurological disorders including Alzheimer’s disease, Huntington’s disease, stroke, TBI, epilepsy 
and Parkinson’s disease. There is a lot of controversy associated with the data obtained from 
clinical trials exploring the GH/IGF-1 axis in aging, neurodegeneration and stroke as reviewed in 
(Gubbi et al., 2018), suggesting the involvement of multiple cell types in progressing the disease. 
Interestingly, glutamatergic dysregulation is a feature of most of these disorders (Miladinovic et 
al., 2015). Additionally, as discussed in the previous chapter, dysregulated urea levels are a 
feature of HD and an early indication of dementia (Handley et al., 2017). Our data clearly 
indicates that deficiency of astrocytic IGFR causes an increase in the overall glutamate, aspartate 
as well as urea levels in the brains of male aIGFR-KO mice. By dysregulating the glutamate-
glutamine cycle, a deficiency of astrocytic IGFR signaling can lead to astrocyte dysfunction and 
elevate susceptibility in males to develop neurological disorders. 
Future studies should examine the contribution of astrocytes to age-related cognitive 
decline with IGF1 deficiency in middle aged (10-14 months) and old (18-24 months) male and 
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female mice with astrocytic IGFR deficiency. Specifically, spatial learning and memory, 
anxiety- like and depression-like behavior, and locomotion should be assessed. Molecular 
pathways associated with glutamate-glutamine cycling should also be assessed. Furthermore, 
involvement of other cells like endothelial cells, microglia in response to IGF1 deficiency should 
be studied. Additionally, in the disorders with disrupted extracellular glutamate homeostasis, the 
contribution of individual cell types needs to be explored to determine if the deficiency in IGF-
1 is beneficial or detrimental. Needless to say, with every induced cell-specific IGF-1 deficiency, 
the effect of sex should always be considered. 
Studying hybrid-receptor signaling in response to a deficiency of aIGFR-KO 
Studies have shown that in all the cells expressing both IR and IGFR, hybrid receptors 
IRA-IGF1R and IRB-IGF1R are formed between the both of them. Some of these are implicated 
to be overexpressed in several cancers, diabetes and other metabolic disorders (Bailyes et al., 
1997; Pandini et al., 2002). In the brain, about half of the receptors exists as hybrid receptors 
than homodimers. Interestingly, these receptors show more affinity towards IGF1 and IGF2, 
and not insulin (Bailyes et al., 1997). Another study has reported contradictory result suggesting 
insulin binds to the receptor IRA-IGF1R with more affinity than IGF-1 and IGF-2 (Pandini et 
al., 2002). A lot of controversy exists in whether insulin or IGF-1 plays a role in AD associated 
cognitive decline and impaired metabolism. 
Based on these observations, if IGF-1 is a more potent ligand for activation of hybrid 
receptors, a reduction in aIGFR would decrease the overall Insulin/IGF-1 receptor as less hybrid 
receptors would be available to bind to IGF1. Thus, this model could possibly be used to study 
the role of astrocytic hybrid Insulin/IGF1Rs (which would form the major proportion of hybrid 
receptors in the brain) in mediating astrocyte dysfunction and cognitive impairment seen in AD. 
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It may also be a potential target in cancers overexpressing these hybrid receptors. 
Conclusion 
Overall, the work described helped answer questions regarding the contribution of 
astrocytes in the age-associated cognitive decline as well as the pathology of any disease linked 
to IGF-1 deficiency. Our data indicates that IGF-1 regulates astrocyte glutamate handling in 
culture as well as in vivo. With IGF1 decline, not only glutamate buffering, but also its 
metabolism is affected. This would ultimately lead to an excitotoxic state in the brain, 
accompanied by disrupted bioenergetics. Thus, the work described here supports the role of IGF- 
1 in regulation of astrocyte structure, function, and cognition. 
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